{"gene":"ACVRL1","run_date":"2026-04-28T17:12:37","timeline":{"discoveries":[{"year":2003,"finding":"ALK1 induces Smad1/5 phosphorylation in endothelial cells, leading to increased proliferation and migration, while acting as an antagonist of the ALK5/Smad2/3 pathway. ALK5 kinase activity is required for TGFβ-dependent recruitment of ALK1 into a TGFβ receptor complex and for optimal ALK1 activation. ALK1 directly antagonizes ALK5/Smad signaling.","method":"Endothelial cell signaling assays, loss-of-function (ALK5-deficient cells), reporter assays, co-immunoprecipitation","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal methods (KO cells, reporter assays, Co-IP), replicated context, high citation count","pmids":["14580334"],"is_preprint":false},{"year":1999,"finding":"ALK1 specifically phosphorylates and activates Smad1. The specificity of Smad1 recognition by ALK1 requires both the receptor L45 loop and two surface structures on the Smad1 MH2 domain (L3 loop and alpha-helix 1), a mechanism distinct from that used by BMPR-I to activate Smad1.","method":"In vitro kinase assays, mutagenesis of L45 loop and Smad MH2 domain, specificity mapping","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with mutagenesis, foundational mechanistic study","pmids":["9920917"],"is_preprint":false},{"year":1999,"finding":"TGFβ1 and TGFβ3, as well as an unidentified serum ligand, can activate ALK1 signaling. The ALK1/TGFβ interaction is mediated by the TGFβ type II receptor. Endoglin binds both ALK1 and TGFβ type I receptor. HHT-associated missense mutations in the ALK1 extracellular domain abrogate signaling.","method":"Chimeric receptor signaling assay (kinase domain swap), PAI-1 promoter reporter, co-immunoprecipitation, mutagenesis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — chimeric receptor functional assay with mutagenesis and co-IP","pmids":["10187774"],"is_preprint":false},{"year":2004,"finding":"Endoglin is required for efficient TGFβ/ALK1 signaling; endothelial cells lacking endoglin show reduced ALK1 signaling and increased ALK5 signaling. Endoglin promotes endothelial cell proliferation by favoring the ALK1 pathway, which indirectly inhibits ALK5 signaling.","method":"Endoglin-deficient endothelial cells, reporter assays, cell proliferation assays, Smad phosphorylation","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 — KO cells with multiple readouts (signaling, proliferation), high citation count","pmids":["15385967"],"is_preprint":false},{"year":2002,"finding":"Disruption of acvrl1 (alk1) in zebrafish results in increased endothelial cell number in specific cranial vessels, causing dilated arteriovenous malformations, establishing ALK1 as a TGFβ type I receptor essential for restricting endothelial cell number during vascular development.","method":"Zebrafish genetic mutant (violet beauregarde), in situ hybridization, endothelial cell counting","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 — clean genetic loss-of-function with specific cellular phenotype, high citation count","pmids":["12050147"],"is_preprint":false},{"year":2010,"finding":"Of 29 TGFβ-related ligands screened, only BMP9 and BMP10 display high-affinity binding to the ALK1 extracellular domain (ALK1-Fc). ALK1-Fc inhibits BMP9-mediated Id-1 expression in endothelial cells and inhibits cord formation on Matrigel.","method":"Surface plasmon resonance ligand screen, cell-based Id-1 reporter assay, Matrigel cord formation assay","journal":"Molecular cancer therapeutics","confidence":"High","confidence_rationale":"Tier 1-2 — SPR binding assay plus functional cell assays, identifies high-affinity ligands","pmids":["20124460"],"is_preprint":false},{"year":2007,"finding":"Conditional endothelial deletion of Alk1 in mice produces severe vascular malformations mimicking all pathological features of HHT2, whereas conditional deletion of Alk5 or Tgfbr2 in endothelial cells (or Alk5 inhibition in zebrafish) does not affect vessel morphogenesis, demonstrating that ALK1's role in HHT pathogenesis is independent of ALK5 and TGFBR2 in vivo.","method":"Conditional endothelial-specific knockout mice (Alk1, Alk5, Tgfbr2), zebrafish Alk5 inhibition, vascular phenotype analysis","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — multiple conditional KO lines with direct phenotypic comparison, genetic epistasis","pmids":["17911384"],"is_preprint":false},{"year":2012,"finding":"ALK1 inhibits angiogenesis by synergizing with the Notch pathway in stalk cells. ALK1-dependent SMAD signaling synergizes with activated Notch to induce HEY1 and HEY2 expression, thereby repressing VEGF signaling, tip cell formation, and endothelial sprouting. BMP9 (high-affinity ALK1 ligand) rescues hypersprouting caused by Notch inhibition.","method":"Postnatal mouse retinal vascular assays, Notch/Alk1 combined blockade, BMP9 rescue, reporter assays in cultured endothelial cells","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic/pharmacological manipulations with defined molecular (HEY1/2) and cellular readouts","pmids":["22421041"],"is_preprint":false},{"year":2013,"finding":"Cardiac-derived BMP10 is the crucial circulating ligand for endothelial ALK1 in embryonic vascular development. Blood flow promotes ALK1 activity by inducing alk1 expression and distributing BMP10, and together these limit endothelial cell number and stabilize nascent arterial caliber.","method":"Zebrafish bmp10 loss-of-function, alk1 expression rescue experiments, flow manipulation, endothelial cell quantification","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis in zebrafish, multiple loss-of-function alleles, defined cellular and molecular phenotypes","pmids":["23863480"],"is_preprint":false},{"year":2012,"finding":"The crystal structure of the ALK1 intracellular kinase domain was determined. ALK1 mediates signaling via phosphorylation of SMAD1/5/8. A small molecule kinase inhibitor (K02288) inhibits BMP9-induced SMAD1/5/8 phosphorylation in endothelial cells and reduces both SMAD-dependent and Notch-dependent transcriptional responses.","method":"Crystal structure determination of ALK1 kinase domain, in vitro kinase inhibition assay, SMAD phosphorylation, reporter assays, endothelial sprouting assays","journal":"Angiogenesis","confidence":"High","confidence_rationale":"Tier 1 — crystal structure plus functional inhibitor assays with multiple readouts","pmids":["25557927"],"is_preprint":false},{"year":2020,"finding":"Crystal structures of the BMP10:ALK1 complex (2.3 Å) and prodomain-bound BMP9:ALK1 complex (3.3 Å) revealed a tripartite recognition mechanism defining BMP9 and BMP10 specificity for ALK1. Introduction of BMP10-specific residues into BMP9 reduced signaling activity, validating the tripartite mechanism.","method":"X-ray crystallography, mutagenesis, C2C12 cell signaling assays, SPR","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 — crystal structures with mutagenesis validation and functional assays","pmids":["32238803"],"is_preprint":false},{"year":2012,"finding":"NMR structure of the ALK1 extracellular domain determined; SPR identified residues in the β4-β5 loop critical for BMP9 binding. The altered conformation of the β4-β5 loop (compared to ALK3) necessitates a ~40° rotated binding mode for BMP9, with a large hydrophobic interface.","method":"NMR structure determination, SPR binding assays, mutagenesis","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — NMR structure with SPR mutational validation","pmids":["22799562"],"is_preprint":false},{"year":2006,"finding":"Smad7 and protein phosphatase 1α (PP1α) are critical determinants of the duration of TGFβ/ALK1 signaling. TGFβ/ALK1 upregulates Smad7 and PP1α; PP1α interacts with ALK1 and this association is potentiated by Smad7; PP1α dephosphorylates ALK1 to terminate Smad1/5 phosphorylation.","method":"siRNA knockdown, ectopic expression, co-immunoprecipitation, phosphatase inhibition assay, reporter assays","journal":"BMC cell biology","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP, siRNA and overexpression with consistent outcomes, enzymatic assay","pmids":["16571110"],"is_preprint":false},{"year":2016,"finding":"ALK1 mediates LDL uptake and transcytosis in endothelial cells via an unusual non-degradative endocytic pathway. ALK1 binds LDL with lower affinity than LDLR and saturates only at hypercholesterolemic concentrations. Endothelium-specific ablation of Alk1 in Ldlr-KO mice reduces LDL uptake into aortic endothelium.","method":"Genome-wide RNAi screen, LDL binding/uptake assays, transcytosis assays, endothelial-specific Alk1 KO mice","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1-2 — genome-wide screen plus in vitro and in vivo validation with genetic KO","pmids":["27869117"],"is_preprint":false},{"year":2023,"finding":"Genetic deletion of ALK1 in arterial endothelial cells substantially limits LDL accumulation, macrophage infiltration, and atherosclerosis without affecting cholesterol levels. A selective monoclonal antibody blocking ALK1 LDL transcytosis (but not BMP9 signaling) dramatically reduces plaque formation in Ldlr-KO mice.","method":"Endothelial-specific Alk1 KO mice, monoclonal antibody blockade, atherosclerosis plaque quantification, LDL transcytosis assay","journal":"Nature cardiovascular research","confidence":"High","confidence_rationale":"Tier 2 — in vivo genetic KO plus antibody intervention with specific molecular dissection of LDL vs. BMP9 pathways","pmids":["39196046"],"is_preprint":false},{"year":2021,"finding":"LUBAC conjugates linear ubiquitin chains onto ALK1, inhibiting its enzyme activity and Smad1/5 activation. OTULIN deubiquitinates ALK1 to promote Smad1/5 activation. EC-specific Otulin deletion causes arteriovenous malformations. HHT2 patient-derived mutant ALK1 exhibits excessive linear ubiquitination and increased HOIP binding.","method":"EC-specific Otulin KO mice, co-immunoprecipitation, ubiquitination assays, SMAD signaling assays, constitutively active ALK1 knockin rescue","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic models, Co-IP, ubiquitination assays, rescue experiment with defined molecular mechanism","pmids":["34157307"],"is_preprint":false},{"year":2007,"finding":"ALK1 localizes to endothelial caveolae and physically interacts with caveolin-1 via the caveolin-1 scaffolding domain and the ALK1 caveolin-1 binding motif. Caveolin-1 enhances TGFβ/ALK1 signaling (opposite to its effect on ALK5). Caveolin-1 suppression abrogates ALK1 signaling.","method":"Confocal microscopy, cholesterol depletion, co-immunoprecipitation, domain mapping, ALK1-specific luciferase reporters, siRNA knockdown","journal":"Cardiovascular research","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP with domain mapping, localization plus functional consequence demonstrated","pmids":["18065769"],"is_preprint":false},{"year":2002,"finding":"Nuclear receptor LXRβ binds specifically to the cytoplasmic domain of ALK1 in vitro and in vivo. Activated ALK1 causes translocation of LXRβ from nucleus to cytoplasm, and ALK1 phosphorylates LXRβ primarily on serine residues. LXRβ subsequently inhibits ALK1- and ALK2-mediated transcriptional responses.","method":"In vitro binding assay, co-immunoprecipitation, subcellular fractionation, phosphorylation assay, transcriptional reporter assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP and functional assays from a single lab, moderate follow-up in the field","pmids":["12393874"],"is_preprint":false},{"year":2013,"finding":"SnoN binds directly to ALK1 on the plasma membrane upon ligand binding and facilitates the interaction between ALK1 and Smad1/5, enhancing Smad1/5 phosphorylation. Disruption of SnoN-Smad1/5 interaction impairs Smad1/5 activation, upregulates Smad2/3 activity, and causes arteriovenous malformations and embryonic lethality.","method":"Co-immunoprecipitation, plasma membrane binding assay, Smad phosphorylation assays, genetic mouse model with embryonic phenotype","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 — direct protein interaction mapping, loss-of-function with clear in vivo phenotype and defined molecular mechanism","pmids":["24019535"],"is_preprint":false},{"year":2016,"finding":"ALK1 controls arterial endothelial cell migration within lumenized vessels (rather than proliferation). In alk1-deficient zebrafish, migration against blood flow direction is dampened and migration in the direction of flow is enhanced, altering endothelial cell distribution and arterial caliber.","method":"Live imaging of zebrafish endothelial cells, cell tracking in alk1 mutants, proliferation assays","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 — direct live imaging of cell behavior in genetic mutant with specific cellular phenotype","pmids":["27287800"],"is_preprint":false},{"year":2014,"finding":"Endothelial-specific depletion of Acvrl1 leads to venous enlargement, vascular hyperbranching, and arteriovenous malformations in neonatal retinal angiogenesis. Loss of Acvrl1 is associated with reduced arterial Jag1 expression, decreased pSmad1/5/8, and increased endothelial cell proliferation. Endoglin is markedly downregulated in Acvrl1-depleted endothelial cells, placing Endoglin downstream of Acvrl1 signaling.","method":"Endothelial-specific Acvrl1 conditional KO mice (neonatal and adult), retinal imaging, immunostaining, pSmad quantification","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 — clean endothelial-specific KO with multiple molecular and morphological readouts","pmids":["24896812"],"is_preprint":false},{"year":2018,"finding":"BMP9/ALK1 signaling represses VEGF-mediated PI3K activity by promoting PTEN activity. Loss of ALK1 function results in increased PI3K pathway activity and vascular hyperplasia. Pharmacological PI3K inhibition rescues vascular hyperplasia of ALK1+/- retinas.","method":"ALK1+/- heterozygous mice, retinal endothelial cell analysis, PI3K/PTEN signaling assays, pharmacological PI3K inhibition rescue, HHT2 patient biopsy analysis","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"High","confidence_rationale":"Tier 2 — genetic model plus pharmacological rescue with defined molecular mechanism, validated in human biopsies","pmids":["29449337"],"is_preprint":false},{"year":2020,"finding":"BMP-9 binding to ALK-1 triggers extensive endocytosis of ALK1 mediated by caveolin-1 (CAV-1) and dynamin-2 but not clathrin. CAV-1 knockdown reduces BMP-9-mediated ALK1 internalization, BMP-9-dependent signaling, and gene expression. LDL reduces BMP-9-induced SMAD1/5 phosphorylation, and BMP-9-mediated ALK1 internalization strongly reduces LDL transcytosis.","method":"Endocytosis assays, siRNA knockdown (CAV-1, DNM2, clathrin), SMAD1/5 phosphorylation, LDL transcytosis assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple siRNA knockdowns with consistent mechanistic outcome across signaling and transcytosis readouts","pmids":["33097593"],"is_preprint":false},{"year":2010,"finding":"Functional analysis of 19 ALK1 mutants reproducing HHT2 mutations showed that most are expressed and reach the cell surface but are defective in BMP9 signaling, while extracellular mutants lose BMP9 binding. None exhibit dominant-negative effects on wild-type ALK1 activity, supporting a haploinsufficiency model for HHT2.","method":"Site-directed mutagenesis, BMP9 signaling reporter assays, cell surface expression assays, BMP9 binding assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1-2 — systematic mutagenesis of 19 HHT2 alleles with functional assays, mechanistic conclusion about haploinsufficiency","pmids":["20501893"],"is_preprint":false},{"year":2022,"finding":"BMP9/BMP10/ALK1 signaling controls the identity and self-renewal of Kupffer cells (KCs) through a Smad4-dependent pathway. ALK1 is dispensable for macrophages in lung, kidney, spleen, and brain. ALK1 deletion causes KC loss over time, replaced by monocyte-derived macrophages with reduced VSIG4 expression, impairing Listeria monocytogenes capture.","method":"Macrophage/KC-specific Alk1 KO mice, flow cytometry, bacterial infection challenge, immunostaining","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — clean genetic KO with defined cellular and functional phenotype across multiple tissue macrophage types","pmids":["34874921"],"is_preprint":false},{"year":2022,"finding":"FOXF1 transcription factor, acting synergistically with ETS factor FLI1, activates the ACVRL1 promoter. Loss of FOXF1 reduces BMP9/ACVRL1 signaling in pulmonary endothelial progenitor cells. Nanoparticle-mediated silencing of ACVRL1 in newborn mice decreases neonatal lung angiogenesis. BMP9 treatment restores lung angiogenesis in ACVRL1-deficient mice.","method":"scRNA-seq, ACVRL1 promoter reporter assays, FOXF1/FLI1 co-transfection, nanoparticle siRNA delivery KO in vivo, BMP9 rescue","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — promoter assay identifies upstream regulators, in vivo KO and rescue with defined angiogenic phenotype","pmids":["35440116"],"is_preprint":false},{"year":2017,"finding":"AMPK activation by metformin inhibits ALK1-mediated Smad1/5 phosphorylation and BMP9-induced tube formation. This is mediated by AMPK-induced upregulation of Smurf1, leading to degradation of ALK1 protein.","method":"Pharmacological AMPK activation, dominant-negative and constitutively-active AMPKα1 constructs, Smad1/5 phosphorylation assays, Smurf1 expression assays, Matrigel angiogenesis assay","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 — multiple genetic and pharmacological tools, single lab, moderate mechanistic follow-up","pmids":["28427181"],"is_preprint":false},{"year":2011,"finding":"Alk1 expression in arterial endothelial cells requires blood flow. In alk1-deficient zebrafish, initial increases in endothelial cell number are independent of blood flow, but later increases and AVM development are flow-dependent. Alk1 transduces hemodynamic forces into a biochemical signal limiting nascent arterial caliber.","method":"Zebrafish alk1 mutant analysis, blood flow manipulation, flow-responsive gene expression analysis, endothelial cell counting","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 — genetic mutant with blood flow manipulation, clear temporal dissection of flow-dependent vs. independent effects","pmids":["21389051"],"is_preprint":false},{"year":2000,"finding":"In COS-1 cells, ALK1 is found in TGFβ1 and TGFβ3 receptor complexes in association with endoglin and TβRII. In HUVEC, ALK1 and endoglin interact directly by co-immunoprecipitation in the absence of ligand, forming a transient association.","method":"Co-immunoprecipitation, immunoprecipitation/western blot in HUVEC and COS-1 cells, novel anti-ALK1 polyclonal antibody","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 3 — single Co-IP from two cell systems, but consistent findings across multiple patient-derived HUVEC","pmids":["10767348"],"is_preprint":false},{"year":2013,"finding":"In chondrocytes, BMP9 potently induces pSmad1/5 phosphorylation and a hypertrophy-like state (bAlpl, bColX expression). BMP9-induced Smad1/5 activation and hypertrophy markers are antagonized by TGFβ1.","method":"Primary bovine chondrocyte cultures, BMP9 stimulation, Western blot (pSmad), qPCR, reporter assay","journal":"Osteoarthritis and cartilage","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro with multiple readouts from single lab","pmids":["25681563"],"is_preprint":false},{"year":2019,"finding":"Somatic mutations resulting in bi-allelic loss of ACVRL1 (in trans with germline mutation) were identified in 9/19 HHT telangiectasia by next-generation sequencing, supporting a Knudsonian two-hit mechanism for focal vascular malformation development rather than haploinsufficiency alone.","method":"Next-generation sequencing of telangiectasia tissue, phase determination of somatic/germline mutations","journal":"American journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 3 — sequencing-based finding establishing mechanism; single study with 19 lesions","pmids":["31630786"],"is_preprint":false},{"year":2013,"finding":"Glucocorticoids promote TGFβ signaling through the Acvrl1/Smad1/5/8 axis and blunt Tgfbr1/Smad2/3 signaling in lung fibroblasts. This shift is mediated by glucocorticoid-induced upregulation of the accessory receptor Tgfbr3 (betaglycan), which acts as a 'switch' potentiating Acvrl1/Smad1 while blunting Tgfbr1/Smad2/3 signaling.","method":"Multiple glucocorticoid treatments, primary lung fibroblasts and endothelial cells, Smad phosphorylation, siRNA for Tgfbr3, in vivo dexamethasone administration to mice","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — multiple cell types and in vivo validation, single lab","pmids":["24347165"],"is_preprint":false},{"year":2022,"finding":"Hepatic endothelial ALK1 signaling (via BMP9/ALK1/ID axis) regulates Wnt2 and R-spondin-3 expression in liver sinusoidal endothelial cells, maintaining metabolic liver zonation. Loss of ALK1 in hepatic endothelial cells leads to vascular malformations, loss of LSEC identity, and disruption of metabolic liver zonation.","method":"LSEC-selective Acvrl1 KO mice (Stab2-iCreF3), transcriptomics, ID1-3 function inhibition, in vitro ALK1 stimulation/inhibition in LSEC","journal":"Hepatology (Baltimore, Md.)","confidence":"High","confidence_rationale":"Tier 2 — cell-type-specific KO with transcriptomic and functional validation, human HHT liver specimen confirmation","pmids":["35776660"],"is_preprint":false},{"year":2012,"finding":"BMP9 induces EphrinB2 expression in arterial endothelial cells through an ALK1-BMPRII/ActRII-ID1/ID3-dependent pathway. Loss of ALK1 reduces EphrinB2 expression, increases VEGFR2 expression, and enhances capillary sprouting and arteriovenous anastomosis.","method":"siRNA knockdown (ALK1, BMPRII, ActRII, ID1, ID3), BMP9 stimulation, immunostaining, in vitro angiogenesis assay","journal":"Angiogenesis","confidence":"Medium","confidence_rationale":"Tier 2 — systematic knockdown of pathway components with defined molecular and cellular readouts, single lab","pmids":["22622516"],"is_preprint":false},{"year":2019,"finding":"In zebrafish, combined loss of bmp10 and bmp10-like (but not bmp9) results in embryonic lethal cranial AVMs indistinguishable from acvrl1 mutants. In juvenile-to-adult period, bmp10 (not bmp9 or bmp10-like) is the non-redundant ALK1 ligand required to maintain the post-embryonic vasculature.","method":"Zebrafish genetic mutants (bmp9, bmp10, bmp10-like single and compound), vascular phenotype analysis","journal":"Angiogenesis","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic mutant combinations establishing ligand hierarchy, clean phenotypic readout","pmids":["31828546"],"is_preprint":false},{"year":2022,"finding":"ALK1 is localized to Caveolin-1-positive early endosomes under atheroprone (low laminar) shear stress conditions, and this endosomal compartment constitutes a signaling hub for BMP9-ALK1-Endoglin-SMAD1 signaling. Endoglin knockdown under these conditions exacerbates SMAD1/5 phosphorylation.","method":"Confocal microscopy, subcellular fractionation, siRNA knockdown, long-term shear stress application in HUVECs","journal":"BMC biology","confidence":"Medium","confidence_rationale":"Tier 2 — direct localization with functional consequence, single lab","pmids":["36171573"],"is_preprint":false},{"year":2005,"finding":"Functional analysis of 11 HHT2-related ALK1 kinase domain mutations revealed two mechanisms: some mutations generate a dominant-negative effect while others result in null phenotypes via loss of protein expression or receptor activity.","method":"Site-directed mutagenesis, reporter assay in mammalian cells, zebrafish embryo injection","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 — systematic mutagenesis with in vitro and in vivo functional validation, single lab","pmids":["16282348"],"is_preprint":false}],"current_model":"ACVRL1 (ALK1) is an endothelial-specific transmembrane serine/threonine kinase receptor for BMP9 and BMP10 (high-affinity ligands) that signals by phosphorylating Smad1/5 (facilitated by SnoN, regulated by Smad7/PP1α-mediated dephosphorylation and LUBAC/OTULIN-mediated linear ubiquitination), antagonizes ALK5/Smad2/3 signaling to promote endothelial cell proliferation and directed migration, cooperates with Notch to repress tip cell formation, represses PI3K activity via PTEN to maintain vascular quiescence, mediates non-degradative LDL transcytosis in endothelial cells via caveolin-1-dependent endocytosis, and its loss causes arteriovenous malformations through a two-hit (haploinsufficiency plus somatic second-hit) mechanism involving flow-dependent failure to limit arterial caliber."},"narrative":{"teleology":[{"year":1999,"claim":"Establishing ALK1 as a Smad1-specific kinase resolved which downstream effector this orphan receptor activated, revealing that specificity depends on the L45 loop and Smad1 MH2 domain surfaces distinct from canonical BMP receptors.","evidence":"In vitro kinase assays with L45 loop and MH2 domain mutagenesis","pmids":["9920917"],"confidence":"High","gaps":["Endogenous ligands for ALK1 not yet identified","In vivo relevance of Smad1 specificity not demonstrated"]},{"year":1999,"claim":"Demonstrating that TGFβ activates ALK1 via the type II receptor TβRII and that endoglin participates in the complex identified ALK1 as a TGFβ superfamily receptor and explained why HHT mutations in both ALK1 and endoglin cause overlapping disease.","evidence":"Chimeric receptor signaling assays, co-immunoprecipitation, HHT missense mutation analysis","pmids":["10187774","10767348"],"confidence":"High","gaps":["Whether TGFβ is the physiologically relevant ligand in vivo remained uncertain","Endoglin's precise role in promoting ALK1 vs. ALK5 signaling not yet defined"]},{"year":2002,"claim":"Genetic loss of alk1 in zebrafish produced dilated AVMs with excess endothelial cells, establishing for the first time that ALK1 restricts endothelial cell number and prevents arteriovenous shunting in vivo.","evidence":"Zebrafish alk1 mutant (violet beauregarde), endothelial cell counting, in situ hybridization","pmids":["12050147"],"confidence":"High","gaps":["Mechanism by which ALK1 limits endothelial cell number unknown","Mammalian in vivo confirmation pending"]},{"year":2003,"claim":"Showing that ALK1 directly antagonizes ALK5/Smad2/3 signaling and requires ALK5 kinase activity for its own activation established the ALK1-ALK5 balance model governing endothelial proliferation versus quiescence.","evidence":"ALK5-deficient endothelial cells, reporter assays, co-immunoprecipitation","pmids":["14580334"],"confidence":"High","gaps":["Whether the ALK5-dependence of ALK1 activation applies in all vascular beds not tested"]},{"year":2004,"claim":"Demonstrating that endoglin-null endothelial cells show impaired ALK1 signaling and enhanced ALK5 signaling resolved endoglin's function as a facilitator that biases TGFβ signaling toward the ALK1/Smad1/5 arm.","evidence":"Endoglin-deficient endothelial cells, Smad phosphorylation and proliferation assays","pmids":["15385967"],"confidence":"High","gaps":["Structural basis for endoglin-ALK1 cooperation unknown","Whether endoglin is required for BMP9/10-ALK1 signaling not addressed"]},{"year":2006,"claim":"Identification of Smad7 and PP1α as negative regulators that dephosphorylate ALK1 defined the signal termination mechanism for the ALK1/Smad1/5 pathway.","evidence":"Co-immunoprecipitation, siRNA, phosphatase inhibition assays, reporter assays","pmids":["16571110"],"confidence":"High","gaps":["In vivo relevance of PP1α-mediated ALK1 dephosphorylation not tested"]},{"year":2007,"claim":"Conditional endothelial Alk1 deletion in mice recapitulated HHT2 while Alk5 and Tgfbr2 deletion did not, overturning the model that ALK1 requires ALK5/TβRII in vivo and implying a distinct ligand drives ALK1 in endothelium.","evidence":"Conditional endothelial-specific KO mice (Alk1, Alk5, Tgfbr2), zebrafish ALK5 inhibition","pmids":["17911384"],"confidence":"High","gaps":["The identity of the in vivo ALK1 ligand in endothelium remained unknown"]},{"year":2007,"claim":"Localization of ALK1 to caveolae and identification of a direct caveolin-1 interaction that enhances ALK1 signaling established the membrane microdomain required for ALK1 signal transduction.","evidence":"Confocal microscopy, co-immunoprecipitation with domain mapping, siRNA knockdown of caveolin-1","pmids":["18065769"],"confidence":"High","gaps":["Whether caveolin-1 dependence extends to BMP9/10-specific ALK1 signaling not yet tested"]},{"year":2010,"claim":"A systematic screen of 29 TGFβ-family ligands identified BMP9 and BMP10 as the sole high-affinity ALK1 ligands, resolving a long-standing question about the physiological activators of ALK1 in endothelium.","evidence":"Surface plasmon resonance ligand screen, Id-1 reporter and Matrigel assays","pmids":["20124460"],"confidence":"High","gaps":["Relative contributions of BMP9 vs. BMP10 in vivo unclear","Whether other ligands activate ALK1 in non-endothelial contexts not excluded"]},{"year":2010,"claim":"Systematic functional analysis of 19 HHT2 mutations showed most retain surface expression but lose BMP9 signaling without dominant-negative effects, supporting haploinsufficiency as the primary disease mechanism.","evidence":"Site-directed mutagenesis, BMP9 reporter and binding assays, surface expression quantification","pmids":["20501893"],"confidence":"High","gaps":["Somatic second-hit mechanism not yet investigated","Earlier study found some kinase domain mutations with dominant-negative activity (PMID:16282348), creating unresolved discrepancy"]},{"year":2011,"claim":"Demonstrating that blood flow induces alk1 expression and that AVM progression is flow-dependent established ALK1 as a mechanosensitive transducer that converts hemodynamic force into a biochemical signal limiting arterial caliber.","evidence":"Zebrafish alk1 mutant with blood flow manipulation, endothelial cell counting","pmids":["21389051"],"confidence":"High","gaps":["Molecular mechanism of flow-induced ALK1 expression unknown","Whether this applies to mammalian vasculature not directly shown"]},{"year":2012,"claim":"Showing that ALK1/Smad signaling synergizes with Notch to induce HEY1/HEY2 and repress tip cell formation unified two major pathways controlling angiogenic sprouting and explained why ALK1 loss causes hypersprouting.","evidence":"Postnatal mouse retinal assays, combined Notch/Alk1 blockade, BMP9 rescue","pmids":["22421041"],"confidence":"High","gaps":["Direct physical interaction between ALK1-Smad and Notch pathways at chromatin level not demonstrated"]},{"year":2012,"claim":"NMR and crystal structures of the ALK1 extracellular domain and kinase domain provided the first atomic-level understanding of ALK1 architecture and revealed an unusual β4-β5 loop conformation requiring a rotated BMP9 binding mode.","evidence":"NMR and X-ray crystallography, SPR mutagenesis validation","pmids":["22799562","25557927"],"confidence":"High","gaps":["Full ternary complex structure with type II receptor not available"]},{"year":2013,"claim":"Identification of cardiac BMP10 as the crucial circulating ALK1 ligand during embryonic vascular development, distributed by blood flow, connected ligand identity, hemodynamics, and ALK1 signaling into an integrated model of arterial caliber control.","evidence":"Zebrafish bmp10 loss-of-function, flow manipulation, alk1 expression rescue","pmids":["23863480"],"confidence":"High","gaps":["Whether BMP9 serves a distinct postnatal role not resolved in this model"]},{"year":2013,"claim":"Discovery that SnoN directly binds ALK1 at the plasma membrane and facilitates Smad1/5 phosphorylation identified a previously unknown positive regulator whose disruption causes AVMs and embryonic lethality.","evidence":"Co-immunoprecipitation, Smad phosphorylation assays, genetic mouse model","pmids":["24019535"],"confidence":"High","gaps":["Whether SnoN facilitates BMP9 vs. BMP10 signaling differentially is untested"]},{"year":2016,"claim":"A genome-wide RNAi screen identified ALK1 as a mediator of non-degradative LDL transcytosis in endothelial cells, revealing a signaling-independent function of ALK1 with direct relevance to cholesterol transport.","evidence":"Genome-wide RNAi screen, LDL binding/uptake/transcytosis assays, endothelial-specific Alk1 KO in Ldlr-KO mice","pmids":["27869117"],"confidence":"High","gaps":["Structural basis for ALK1-LDL interaction unknown","Whether LDL transcytosis and BMP signaling can be pharmacologically separated not yet shown"]},{"year":2016,"claim":"Live imaging in alk1 mutant zebrafish revealed that ALK1 controls directed endothelial migration against blood flow rather than proliferation in lumenized arteries, refining the cellular mechanism of AVM formation.","evidence":"Live endothelial cell tracking in zebrafish alk1 mutants, proliferation quantification","pmids":["27287800"],"confidence":"High","gaps":["Molecular mediators downstream of ALK1 that direct migration not identified"]},{"year":2018,"claim":"Demonstrating that ALK1 loss increases PI3K activity through reduced PTEN function, and that PI3K inhibition rescues ALK1-haploinsufficient vascular hyperplasia, identified a druggable effector pathway downstream of ALK1.","evidence":"ALK1+/- mice, retinal analysis, PI3K/PTEN signaling assays, pharmacological rescue, HHT2 patient biopsies","pmids":["29449337"],"confidence":"High","gaps":["Mechanism by which Smad1/5 signaling activates PTEN not defined"]},{"year":2019,"claim":"Identification of somatic second-hit ACVRL1 mutations in HHT telangiectasia supported a Knudsonian two-hit model, explaining why vascular malformations are focal despite germline haploinsufficiency.","evidence":"Next-generation sequencing of 19 telangiectasia lesions, phasing of somatic and germline mutations","pmids":["31630786"],"confidence":"Medium","gaps":["Only 9/19 lesions showed biallelic loss; alternative mechanisms in remaining lesions unknown","Independent replication in larger cohorts needed"]},{"year":2020,"claim":"Crystal structures of BMP10:ALK1 and prodomain-bound BMP9:ALK1 complexes defined the tripartite recognition mechanism for ligand specificity, explaining why only BMP9 and BMP10 activate ALK1.","evidence":"X-ray crystallography (2.3 and 3.3 Å), mutagenesis, SPR, cell signaling assays","pmids":["32238803"],"confidence":"High","gaps":["Full hexameric complex with type II receptor and endoglin not structurally resolved"]},{"year":2020,"claim":"Showing that BMP9-triggered ALK1 internalization is caveolin-1/dynamin-2-dependent and competes with LDL transcytosis mechanistically linked ALK1's signaling and transport functions through shared endocytic machinery.","evidence":"Endocytosis assays with siRNA knockdown of CAV-1, DNM2, and clathrin; SMAD1/5 phosphorylation and LDL transcytosis quantification","pmids":["33097593"],"confidence":"High","gaps":["Whether caveolar vs. endosomal ALK1 pools are functionally distinct in vivo is unclear"]},{"year":2021,"claim":"Discovery that LUBAC conjugates linear ubiquitin chains onto ALK1 to inhibit its kinase activity, reversed by OTULIN, identified a novel post-translational regulatory layer; HHT2-mutant ALK1 shows excessive linear ubiquitination, linking this mechanism directly to disease.","evidence":"EC-specific Otulin KO mice, ubiquitination assays, co-immunoprecipitation, constitutively active ALK1 rescue","pmids":["34157307"],"confidence":"High","gaps":["Which specific lysine residues on ALK1 are ubiquitinated not mapped","Whether LUBAC/OTULIN regulation affects LDL transcytosis is unknown"]},{"year":2022,"claim":"Extending ALK1 function beyond endothelium, BMP9/BMP10/ALK1 signaling was shown to control Kupffer cell identity and self-renewal through Smad4, with ALK1 loss causing KC replacement by monocyte-derived macrophages and impaired pathogen capture.","evidence":"Macrophage/KC-specific Alk1 KO mice, flow cytometry, Listeria infection challenge","pmids":["34874921"],"confidence":"High","gaps":["Downstream transcriptional targets of ALK1 in Kupffer cells not fully characterized","Whether this represents a direct cell-autonomous function or paracrine effect not fully excluded"]},{"year":2022,"claim":"Identification of FOXF1 and FLI1 as transcriptional activators of the ACVRL1 promoter, combined with in vivo demonstration that ACVRL1 silencing impairs neonatal lung angiogenesis, defined the upstream regulatory circuit controlling ALK1 expression in pulmonary endothelium.","evidence":"scRNA-seq, promoter reporter assays, nanoparticle siRNA in vivo knockdown, BMP9 rescue","pmids":["35440116"],"confidence":"High","gaps":["Whether FOXF1-dependent regulation is specific to lung endothelium or generalizable is unknown"]},{"year":2022,"claim":"Hepatic endothelial ALK1 signaling through the BMP9/ALK1/ID axis was shown to regulate Wnt2 and R-spondin-3 expression, maintaining liver sinusoidal endothelial cell identity and metabolic zonation.","evidence":"LSEC-selective Acvrl1 KO mice, transcriptomics, ID function inhibition, HHT liver specimens","pmids":["35776660"],"confidence":"High","gaps":["Whether ALK1 regulates Wnt signaling in other organ vasculatures is unexplored"]},{"year":2023,"claim":"A monoclonal antibody that selectively blocks ALK1-mediated LDL transcytosis without disrupting BMP9 signaling dramatically reduced atherosclerosis, demonstrating therapeutic separability of ALK1's dual functions.","evidence":"Endothelial-specific Alk1 KO mice, selective monoclonal antibody, plaque quantification in Ldlr-KO mice","pmids":["39196046"],"confidence":"High","gaps":["Long-term vascular safety of selective LDL-transcytosis blockade not assessed","Structural epitope on ALK1 responsible for LDL binding versus BMP9 binding not mapped"]},{"year":null,"claim":"Key unresolved questions include the structural basis for ALK1-LDL interaction, how flow-sensing is molecularly transduced through ALK1, the full hexameric receptor complex structure with type II receptors, and whether the two-hit mechanism accounts for all HHT2 vascular malformations.","evidence":"","pmids":[],"confidence":"High","gaps":["No structural model of ALK1-LDL binding interface","Mechanotransduction mechanism linking shear stress to ALK1 activation undefined","Complete receptor signaling complex structure not solved","Two-hit model only validated in ~50% of lesions"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1,9,12,15,18]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,7,21]},{"term_id":"GO:0038024","term_label":"cargo receptor activity","supporting_discovery_ids":[13,14,22]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[16,18,22,35]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[22,35]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[22,35]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,5,7,9,10,12,15,18,21]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[4,8,20,27]},{"term_id":"R-HSA-382551","term_label":"Transport of small molecules","supporting_discovery_ids":[13,14,22]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[23,30,36]}],"complexes":["TGFβ/BMP receptor complex (ALK1-TβRII-endoglin)","BMP9/10-ALK1-BMPRII/ActRII signaling complex"],"partners":["ENG","SMAD1","SMAD5","CAV1","SKIL","SMAD7","PPP1CA","HOIP"],"other_free_text":[]},"mechanistic_narrative":"ACVRL1 (ALK1) is an endothelial type I serine/threonine kinase receptor that transduces BMP9/BMP10 signals through Smad1/5 phosphorylation to control vascular morphogenesis, endothelial quiescence, and arterial caliber. ALK1 recognizes BMP9 and BMP10 as high-affinity ligands via a tripartite binding mechanism involving its β4-β5 loop, signals through caveolin-1-dependent endocytosis, and synergizes with Notch to repress tip cell formation and VEGF signaling; its activity is positively regulated by the adaptor SnoN and endoglin, and negatively regulated by Smad7/PP1α-mediated dephosphorylation and LUBAC-mediated linear ubiquitination [PMID:20124460, PMID:32238803, PMID:22421041, PMID:24019535, PMID:15385967, PMID:16571110, PMID:34157307, PMID:33097593]. Beyond canonical BMP signaling, ALK1 mediates non-degradative LDL transcytosis across endothelium; arterial endothelial-specific ALK1 deletion reduces atherosclerotic plaque formation, and a monoclonal antibody selectively blocking LDL transcytosis without disrupting BMP9 signaling recapitulates this protection [PMID:27869117, PMID:39196046]. Loss-of-function mutations in ACVRL1 cause hereditary hemorrhagic telangiectasia type 2 (HHT2), with somatic second-hit mutations driving focal arteriovenous malformations through a Knudsonian two-hit mechanism compounded by flow-dependent failure to limit arterial caliber [PMID:20501893, PMID:31630786, PMID:21389051]."},"prefetch_data":{"uniprot":{"accession":"P37023","full_name":"Activin receptor type-1-like","aliases":["Activin receptor-like kinase 1","ALK-1","Serine/threonine-protein kinase receptor R3","SKR3","TGF-B superfamily receptor type I","TSR-I"],"length_aa":503,"mass_kda":56.1,"function":"Type I receptor for TGF-beta family ligands BMP9/GDF2 and BMP10 and important regulator of normal blood vessel development. On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. May bind activin as well","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/P37023/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ACVRL1","classification":"Not Classified","n_dependent_lines":3,"n_total_lines":1208,"dependency_fraction":0.0024834437086092716},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ACVRL1","total_profiled":1310},"omim":[{"mim_id":"620997","title":"SEMAPHORIN 3G; SEMA3G","url":"https://www.omim.org/entry/620997"},{"mim_id":"616334","title":"TRANSMEMBRANE PROTEIN 100; TMEM100","url":"https://www.omim.org/entry/616334"},{"mim_id":"615506","title":"TELANGIECTASIA, HEREDITARY HEMORRHAGIC, TYPE 5; HHT5","url":"https://www.omim.org/entry/615506"},{"mim_id":"609810","title":"PATERNALLY EXPRESSED GENE 10; PEG10","url":"https://www.omim.org/entry/609810"},{"mim_id":"605120","title":"GROWTH/DIFFERENTIATION FACTOR 2; GDF2","url":"https://www.omim.org/entry/605120"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"lung","ntpm":83.2}],"url":"https://www.proteinatlas.org/search/ACVRL1"},"hgnc":{"alias_symbol":["HHT2","ALK1","HHT"],"prev_symbol":["ACVRLK1","ORW2"]},"alphafold":{"accession":"P37023","domains":[{"cath_id":"2.10.60.10","chopping":"28-96","consensus_level":"medium","plddt":83.3452,"start":28,"end":96},{"cath_id":"3.30.200.20","chopping":"199-277","consensus_level":"high","plddt":92.0648,"start":199,"end":277},{"cath_id":"1.10.510.10","chopping":"283-493","consensus_level":"high","plddt":95.2282,"start":283,"end":493}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P37023","model_url":"https://alphafold.ebi.ac.uk/files/AF-P37023-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P37023-F1-predicted_aligned_error_v6.png","plddt_mean":82.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ACVRL1","jax_strain_url":"https://www.jax.org/strain/search?query=ACVRL1"},"sequence":{"accession":"P37023","fasta_url":"https://rest.uniprot.org/uniprotkb/P37023.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P37023/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P37023"}},"corpus_meta":[{"pmid":"14580334","id":"PMC_14580334","title":"Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling.","date":"2003","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/14580334","citation_count":593,"is_preprint":false},{"pmid":"15385967","id":"PMC_15385967","title":"Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction.","date":"2004","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/15385967","citation_count":551,"is_preprint":false},{"pmid":"12050147","id":"PMC_12050147","title":"Disruption of acvrl1 increases endothelial cell number in zebrafish cranial vessels.","date":"2002","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/12050147","citation_count":310,"is_preprint":false},{"pmid":"22421041","id":"PMC_22421041","title":"ALK1 signaling inhibits angiogenesis by cooperating with the Notch pathway.","date":"2012","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/22421041","citation_count":302,"is_preprint":false},{"pmid":"19494318","id":"PMC_19494318","title":"Increase in ALK1/ALK5 ratio as a cause for elevated MMP-13 expression in osteoarthritis in humans and mice.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19494318","citation_count":234,"is_preprint":false},{"pmid":"20056902","id":"PMC_20056902","title":"Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation.","date":"2010","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/20056902","citation_count":228,"is_preprint":false},{"pmid":"16613914","id":"PMC_16613914","title":"SMAD4 mutations found in unselected HHT patients.","date":"2006","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16613914","citation_count":184,"is_preprint":false},{"pmid":"17911384","id":"PMC_17911384","title":"ALK5- and TGFBR2-independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17911384","citation_count":184,"is_preprint":false},{"pmid":"9920917","id":"PMC_9920917","title":"Smad1 recognition and activation by the ALK1 group of transforming growth factor-beta family receptors.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9920917","citation_count":181,"is_preprint":false},{"pmid":"21389051","id":"PMC_21389051","title":"Interaction between alk1 and blood flow in the development of arteriovenous malformations.","date":"2011","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/21389051","citation_count":170,"is_preprint":false},{"pmid":"17224686","id":"PMC_17224686","title":"Genotype-phenotype correlations in hereditary hemorrhagic telangiectasia: data from the French-Italian HHT network.","date":"2007","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17224686","citation_count":169,"is_preprint":false},{"pmid":"12588795","id":"PMC_12588795","title":"A mouse model for hereditary hemorrhagic telangiectasia (HHT) type 2.","date":"2003","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12588795","citation_count":148,"is_preprint":false},{"pmid":"18333754","id":"PMC_18333754","title":"ALK1 opposes ALK5/Smad3 signaling and expression of extracellular matrix components in human chondrocytes.","date":"2008","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/18333754","citation_count":132,"is_preprint":false},{"pmid":"27869117","id":"PMC_27869117","title":"Genome-wide RNAi screen reveals ALK1 mediates LDL uptake and transcytosis in endothelial cells.","date":"2016","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/27869117","citation_count":128,"is_preprint":false},{"pmid":"20124460","id":"PMC_20124460","title":"ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth.","date":"2010","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/20124460","citation_count":127,"is_preprint":false},{"pmid":"10187774","id":"PMC_10187774","title":"Assignment of transforming growth factor beta1 and beta3 and a third new ligand to the type I receptor ALK-1.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10187774","citation_count":125,"is_preprint":false},{"pmid":"17388964","id":"PMC_17388964","title":"Hereditary hemorrhagic telangiectasia: clinical features in ENG and ALK1 mutation carriers.","date":"2007","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/17388964","citation_count":122,"is_preprint":false},{"pmid":"16752392","id":"PMC_16752392","title":"Novel mutations in ENG and ACVRL1 identified in a series of 200 individuals undergoing clinical genetic testing for hereditary hemorrhagic telangiectasia (HHT): correlation of genotype with phenotype.","date":"2006","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/16752392","citation_count":115,"is_preprint":false},{"pmid":"24896812","id":"PMC_24896812","title":"Endothelial depletion of Acvrl1 in mice leads to arteriovenous malformations associated with reduced endoglin expression.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24896812","citation_count":114,"is_preprint":false},{"pmid":"31630786","id":"PMC_31630786","title":"Somatic Mutations in Vascular Malformations of Hereditary Hemorrhagic Telangiectasia Result in Bi-allelic Loss of ENG or ACVRL1.","date":"2019","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31630786","citation_count":108,"is_preprint":false},{"pmid":"10767348","id":"PMC_10767348","title":"Analysis of ALK-1 and endoglin in newborns from families with hereditary hemorrhagic telangiectasia type 2.","date":"2000","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10767348","citation_count":103,"is_preprint":false},{"pmid":"18303046","id":"PMC_18303046","title":"L- and S-endoglin differentially modulate TGFbeta1 signaling mediated by ALK1 and ALK5 in L6E9 myoblasts.","date":"2008","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/18303046","citation_count":100,"is_preprint":false},{"pmid":"15024723","id":"PMC_15024723","title":"Molecular screening of ALK1/ACVRL1 and ENG genes in hereditary hemorrhagic telangiectasia in France.","date":"2004","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/15024723","citation_count":95,"is_preprint":false},{"pmid":"23241407","id":"PMC_23241407","title":"Reduced mural cell coverage and impaired vessel integrity after angiogenic stimulation in the Alk1-deficient brain.","date":"2012","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/23241407","citation_count":94,"is_preprint":false},{"pmid":"27287800","id":"PMC_27287800","title":"Alk1 controls arterial endothelial cell migration in lumenized vessels.","date":"2016","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/27287800","citation_count":88,"is_preprint":false},{"pmid":"15517393","id":"PMC_15517393","title":"Hereditary hemorrhagic telangiectasia: ENG and ALK-1 mutations in Dutch patients.","date":"2004","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15517393","citation_count":85,"is_preprint":false},{"pmid":"29449337","id":"PMC_29449337","title":"ALK1 Loss Results in Vascular Hyperplasia in Mice and Humans Through PI3K Activation.","date":"2018","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/29449337","citation_count":84,"is_preprint":false},{"pmid":"24956016","id":"PMC_24956016","title":"Key role of the endothelial TGF-β/ALK1/endoglin signaling pathway in humans and rodents pulmonary hypertension.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24956016","citation_count":83,"is_preprint":false},{"pmid":"28871312","id":"PMC_28871312","title":"ALK1 signaling in development and disease: new paradigms.","date":"2017","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/28871312","citation_count":81,"is_preprint":false},{"pmid":"23863480","id":"PMC_23863480","title":"Circulating Bmp10 acts through endothelial Alk1 to mediate flow-dependent arterial quiescence.","date":"2013","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/23863480","citation_count":80,"is_preprint":false},{"pmid":"28796572","id":"PMC_28796572","title":"Endoglin and alk1 as therapeutic targets for hereditary hemorrhagic telangiectasia.","date":"2017","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/28796572","citation_count":75,"is_preprint":false},{"pmid":"20501893","id":"PMC_20501893","title":"Functional analysis of the BMP9 response of ALK1 mutants from HHT2 patients: a diagnostic tool for novel ACVRL1 mutations.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20501893","citation_count":72,"is_preprint":false},{"pmid":"33290255","id":"PMC_33290255","title":"Coicis semen protects against focal cerebral ischemia-reperfusion injury by inhibiting oxidative stress and promoting angiogenesis via the TGFβ/ALK1/Smad1/5 signaling pathway.","date":"2020","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/33290255","citation_count":71,"is_preprint":false},{"pmid":"10946360","id":"PMC_10946360","title":"Clinical manifestations in a large hereditary hemorrhagic telangiectasia (HHT) type 2 kindred.","date":"2000","source":"American journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10946360","citation_count":69,"is_preprint":false},{"pmid":"32238803","id":"PMC_32238803","title":"Molecular basis of ALK1-mediated signalling by BMP9/BMP10 and their prodomain-bound forms.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32238803","citation_count":67,"is_preprint":false},{"pmid":"31828546","id":"PMC_31828546","title":"BMP10-mediated ALK1 signaling is continuously required for vascular development and maintenance.","date":"2019","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/31828546","citation_count":65,"is_preprint":false},{"pmid":"18065769","id":"PMC_18065769","title":"Caveolin-1 interacts and cooperates with the transforming growth factor-beta type I receptor ALK1 in endothelial caveolae.","date":"2007","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/18065769","citation_count":64,"is_preprint":false},{"pmid":"21859819","id":"PMC_21859819","title":"Pulmonary hypertension in adult Alk1 heterozygous mice due to oxidative stress.","date":"2011","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/21859819","citation_count":63,"is_preprint":false},{"pmid":"24055043","id":"PMC_24055043","title":"ALK1-Smad1/5 signaling pathway in fibrosis development: friend or foe?","date":"2013","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/24055043","citation_count":61,"is_preprint":false},{"pmid":"24463008","id":"PMC_24463008","title":"Canonical Wnt signaling skews TGF-β signaling in chondrocytes towards signaling via ALK1 and Smad 1/5/8.","date":"2014","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/24463008","citation_count":61,"is_preprint":false},{"pmid":"12700602","id":"PMC_12700602","title":"Disease-associated mutations in conserved residues of ALK-1 kinase domain.","date":"2003","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/12700602","citation_count":58,"is_preprint":false},{"pmid":"24347165","id":"PMC_24347165","title":"Glucocorticoids recruit Tgfbr3 and Smad1 to shift transforming growth factor-β signaling from the Tgfbr1/Smad2/3 axis to the Acvrl1/Smad1 axis in lung fibroblasts.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24347165","citation_count":57,"is_preprint":false},{"pmid":"17786384","id":"PMC_17786384","title":"Analysis of ENG and ACVRL1 genes in 137 HHT Italian families identifies 76 different mutations (24 novel). Comparison with other European studies.","date":"2007","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17786384","citation_count":55,"is_preprint":false},{"pmid":"35440116","id":"PMC_35440116","title":"Endothelial progenitor cells stimulate neonatal lung angiogenesis through FOXF1-mediated activation of BMP9/ACVRL1 signaling.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35440116","citation_count":52,"is_preprint":false},{"pmid":"28114930","id":"PMC_28114930","title":"Quality of life in patients with hereditary haemorrhagic telangiectasia (HHT).","date":"2017","source":"Health and quality of life outcomes","url":"https://pubmed.ncbi.nlm.nih.gov/28114930","citation_count":52,"is_preprint":false},{"pmid":"34874921","id":"PMC_34874921","title":"ALK1 signaling is required for the homeostasis of Kupffer cells and prevention of bacterial infection.","date":"2022","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/34874921","citation_count":50,"is_preprint":false},{"pmid":"22632830","id":"PMC_22632830","title":"Outcomes of childhood pulmonary arterial hypertension in BMPR2 and ALK1 mutation carriers.","date":"2012","source":"The American journal of cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/22632830","citation_count":50,"is_preprint":false},{"pmid":"25557927","id":"PMC_25557927","title":"A small molecule targeting ALK1 prevents Notch cooperativity and inhibits functional angiogenesis.","date":"2015","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/25557927","citation_count":49,"is_preprint":false},{"pmid":"16571110","id":"PMC_16571110","title":"Smad7 and protein phosphatase 1alpha are critical determinants in the duration of TGF-beta/ALK1 signaling in endothelial cells.","date":"2006","source":"BMC cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/16571110","citation_count":47,"is_preprint":false},{"pmid":"27528761","id":"PMC_27528761","title":"Regulation of the ALK1 ligands, BMP9 and BMP10.","date":"2016","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/27528761","citation_count":46,"is_preprint":false},{"pmid":"16887821","id":"PMC_16887821","title":"Dual function of the Drosophila Alk1/Alk2 ortholog Saxophone shapes the Bmp activity gradient in the wing imaginal disc.","date":"2006","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/16887821","citation_count":45,"is_preprint":false},{"pmid":"30760892","id":"PMC_30760892","title":"Phenotype of CM-AVM2 caused by variants in EPHB4: how much overlap with hereditary hemorrhagic telangiectasia (HHT)?","date":"2019","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30760892","citation_count":44,"is_preprint":false},{"pmid":"22622516","id":"PMC_22622516","title":"BMP9 induces EphrinB2 expression in endothelial cells through an Alk1-BMPRII/ActRII-ID1/ID3-dependent pathway: implications for hereditary hemorrhagic telangiectasia type II.","date":"2012","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/22622516","citation_count":43,"is_preprint":false},{"pmid":"32082362","id":"PMC_32082362","title":"MiR-199b-5p Suppresses Tumor Angiogenesis Mediated by Vascular Endothelial Cells in Breast Cancer by Targeting ALK1.","date":"2020","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32082362","citation_count":42,"is_preprint":false},{"pmid":"16776339","id":"PMC_16776339","title":"Association of a polymorphism of the ACVRL1 gene with sporadic arteriovenous malformations of the central nervous system.","date":"2006","source":"Journal of neurosurgery","url":"https://pubmed.ncbi.nlm.nih.gov/16776339","citation_count":41,"is_preprint":false},{"pmid":"27528762","id":"PMC_27528762","title":"Targeting tumour vasculature by inhibiting activin receptor-like kinase (ALK)1 function.","date":"2016","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/27528762","citation_count":37,"is_preprint":false},{"pmid":"12419758","id":"PMC_12419758","title":"Primary brain CD30+ ALK1+ anaplastic large cell lymphoma ('ALKoma'): the first case with a combination of 'not common' variants.","date":"2002","source":"Annals of oncology : official journal of the European Society for Medical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/12419758","citation_count":37,"is_preprint":false},{"pmid":"16611099","id":"PMC_16611099","title":"Hereditary Haemorrhagic Telangiectasia (HHT): genetic and molecular aspects.","date":"2006","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/16611099","citation_count":36,"is_preprint":false},{"pmid":"24936649","id":"PMC_24936649","title":"Novel mutations in BMPR2, ACVRL1 and KCNA5 genes and hemodynamic parameters in patients with pulmonary arterial hypertension.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24936649","citation_count":35,"is_preprint":false},{"pmid":"25888978","id":"PMC_25888978","title":"Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229N.","date":"2015","source":"Gynecologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25888978","citation_count":35,"is_preprint":false},{"pmid":"32503579","id":"PMC_32503579","title":"Current HHT genetic overview in Spain and its phenotypic correlation: data from RiHHTa registry.","date":"2020","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/32503579","citation_count":35,"is_preprint":false},{"pmid":"25279424","id":"PMC_25279424","title":"TGF-β & BMP receptors endoglin and ALK1: overview of their functional role and status as antiangiogenic targets.","date":"2014","source":"Microcirculation (New York, N.Y. : 1994)","url":"https://pubmed.ncbi.nlm.nih.gov/25279424","citation_count":34,"is_preprint":false},{"pmid":"25799559","id":"PMC_25799559","title":"Serum induces transcription of Hey1 and Hey2 genes by Alk1 but not Notch signaling in endothelial cells.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25799559","citation_count":34,"is_preprint":false},{"pmid":"22799562","id":"PMC_22799562","title":"Structure of the Alk1 extracellular domain and characterization of its bone morphogenetic protein (BMP) binding properties.","date":"2012","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22799562","citation_count":33,"is_preprint":false},{"pmid":"21378382","id":"PMC_21378382","title":"Mosaic ACVRL1 and ENG mutations in hereditary haemorrhagic telangiectasia patients.","date":"2011","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21378382","citation_count":32,"is_preprint":false},{"pmid":"39196046","id":"PMC_39196046","title":"Genetic or therapeutic neutralization of ALK1 reduces LDL transcytosis and atherosclerosis in mice.","date":"2023","source":"Nature cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/39196046","citation_count":31,"is_preprint":false},{"pmid":"28427181","id":"PMC_28427181","title":"Metformin inhibits ALK1-mediated angiogenesis via activation of AMPK.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28427181","citation_count":31,"is_preprint":false},{"pmid":"26229139","id":"PMC_26229139","title":"BMP9 Induces Cord Blood-Derived Endothelial Progenitor Cell Differentiation and Ischemic Neovascularization via ALK1.","date":"2015","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/26229139","citation_count":31,"is_preprint":false},{"pmid":"34157307","id":"PMC_34157307","title":"OTULIN allies with LUBAC to govern angiogenesis by editing ALK1 linear polyubiquitin.","date":"2021","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/34157307","citation_count":29,"is_preprint":false},{"pmid":"25852751","id":"PMC_25852751","title":"Mononuclear cells and vascular repair in HHT.","date":"2015","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25852751","citation_count":28,"is_preprint":false},{"pmid":"16429404","id":"PMC_16429404","title":"DHPLC-based mutation analysis of ENG and ALK-1 genes in HHT Italian population.","date":"2006","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/16429404","citation_count":28,"is_preprint":false},{"pmid":"33097593","id":"PMC_33097593","title":"BMP-9 and LDL crosstalk regulates ALK-1 endocytosis and LDL transcytosis in endothelial cells.","date":"2020","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33097593","citation_count":28,"is_preprint":false},{"pmid":"25681563","id":"PMC_25681563","title":"The high affinity ALK1-ligand BMP9 induces a hypertrophy-like state in chondrocytes that is antagonized by TGFβ1.","date":"2015","source":"Osteoarthritis and cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/25681563","citation_count":28,"is_preprint":false},{"pmid":"16855400","id":"PMC_16855400","title":"Alk1 and Alk2 are two new cell cycle-regulated haspin-like proteins in budding yeast.","date":"2006","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/16855400","citation_count":27,"is_preprint":false},{"pmid":"27876060","id":"PMC_27876060","title":"20-year follow-up study of Danish HHT patients-survival and causes of death.","date":"2016","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/27876060","citation_count":27,"is_preprint":false},{"pmid":"36525822","id":"PMC_36525822","title":"Metformin suppresses LRG1 and TGFβ1/ALK1-induced angiogenesis and protects against ultrastructural changes in rat diabetic nephropathy.","date":"2022","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/36525822","citation_count":26,"is_preprint":false},{"pmid":"15712270","id":"PMC_15712270","title":"Hepatic manifestation is associated with ALK1 in hereditary hemorrhagic telangiectasia: identification of five novel ALK1 and one novel ENG mutations.","date":"2005","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/15712270","citation_count":26,"is_preprint":false},{"pmid":"27271275","id":"PMC_27271275","title":"For staining of ALK protein, the novel D5F3 antibody demonstrates superior overall performance in terms of intensity and extent of staining in comparison to the currently used ALK1 antibody.","date":"2016","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/27271275","citation_count":26,"is_preprint":false},{"pmid":"35776660","id":"PMC_35776660","title":"ALK1 controls hepatic vessel formation, angiodiversity, and angiocrine functions in hereditary hemorrhagic telangiectasia of the liver.","date":"2022","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/35776660","citation_count":25,"is_preprint":false},{"pmid":"25266657","id":"PMC_25266657","title":"ALK5 and ALK1 play antagonistic roles in transforming growth factor β-induced podosome formation in aortic endothelial cells.","date":"2014","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/25266657","citation_count":25,"is_preprint":false},{"pmid":"16282348","id":"PMC_16282348","title":"Functional analysis of mutations in the kinase domain of the TGF-beta receptor ALK1 reveals different mechanisms for induction of hereditary hemorrhagic telangiectasia.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16282348","citation_count":25,"is_preprint":false},{"pmid":"30251589","id":"PMC_30251589","title":"Mutations in the ENG, ACVRL1, and SMAD4 genes and clinical manifestations of hereditary haemorrhagic telangiectasia: experience from the Center for Osler's Disease, Uppsala University Hospital.","date":"2018","source":"Upsala journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30251589","citation_count":24,"is_preprint":false},{"pmid":"25969392","id":"PMC_25969392","title":"Context-specific interactions between Notch and ALK1 cannot explain ALK1-associated arteriovenous malformations.","date":"2015","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/25969392","citation_count":22,"is_preprint":false},{"pmid":"34674144","id":"PMC_34674144","title":"Bone Marrow-Derived Alk1 Mutant Endothelial Cells and Clonally Expanded Somatic Alk1 Mutant Endothelial Cells Contribute to the Development of Brain Arteriovenous Malformations in Mice.","date":"2021","source":"Translational stroke research","url":"https://pubmed.ncbi.nlm.nih.gov/34674144","citation_count":22,"is_preprint":false},{"pmid":"32842615","id":"PMC_32842615","title":"Genotype-Phenotype Correlations in Children with HHT.","date":"2020","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32842615","citation_count":22,"is_preprint":false},{"pmid":"30809644","id":"PMC_30809644","title":"BMPRII deficiency impairs apoptosis via the BMPRII-ALK1-BclX-mediated pathway in pulmonary arterial hypertension.","date":"2019","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30809644","citation_count":22,"is_preprint":false},{"pmid":"12393874","id":"PMC_12393874","title":"Regulation of ALK-1 signaling by the nuclear receptor LXRbeta.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12393874","citation_count":22,"is_preprint":false},{"pmid":"30584075","id":"PMC_30584075","title":"A theory for polymicrogyria and brain arteriovenous malformations in HHT.","date":"2019","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/30584075","citation_count":21,"is_preprint":false},{"pmid":"26821948","id":"PMC_26821948","title":"Interaction Between ALK1 Signaling and Connexin40 in the Development of Arteriovenous Malformations.","date":"2016","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/26821948","citation_count":20,"is_preprint":false},{"pmid":"26176610","id":"PMC_26176610","title":"Functional and splicing defect analysis of 23 ACVRL1 mutations in a cohort of patients affected by Hereditary Hemorrhagic Telangiectasia.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26176610","citation_count":19,"is_preprint":false},{"pmid":"36171573","id":"PMC_36171573","title":"Atheroprone fluid shear stress-regulated ALK1-Endoglin-SMAD signaling originates from early endosomes.","date":"2022","source":"BMC biology","url":"https://pubmed.ncbi.nlm.nih.gov/36171573","citation_count":18,"is_preprint":false},{"pmid":"34771575","id":"PMC_34771575","title":"The Dual Effect of the BMP9-ALK1 Pathway in Blood Vessels: An Opportunity for Cancer Therapy Improvement?","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34771575","citation_count":17,"is_preprint":false},{"pmid":"24019535","id":"PMC_24019535","title":"SnoN facilitates ALK1-Smad1/5 signaling during embryonic angiogenesis.","date":"2013","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/24019535","citation_count":17,"is_preprint":false},{"pmid":"26391603","id":"PMC_26391603","title":"Executive summary of the 11th HHT international scientific conference.","date":"2015","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/26391603","citation_count":17,"is_preprint":false},{"pmid":"24318419","id":"PMC_24318419","title":"Increased ALK1 copy number and renal cell carcinoma-a case report.","date":"2013","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24318419","citation_count":16,"is_preprint":false},{"pmid":"37743483","id":"PMC_37743483","title":"ACVRL1 drives resistance to multitarget tyrosine kinase inhibitors in colorectal cancer by promoting USP15-mediated GPX2 stabilization.","date":"2023","source":"BMC medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37743483","citation_count":15,"is_preprint":false},{"pmid":"38457357","id":"PMC_38457357","title":"Mutations causing premature termination codons discriminate and generate cellular and clinical variability in HHT.","date":"2024","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/38457357","citation_count":15,"is_preprint":false},{"pmid":"38294582","id":"PMC_38294582","title":"Impact of heterozygous ALK1 mutations on the transcriptomic response to BMP9 and BMP10 in endothelial cells from hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension donors.","date":"2024","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/38294582","citation_count":15,"is_preprint":false},{"pmid":"25847705","id":"PMC_25847705","title":"The ACVRL1 c.314-35A>G polymorphism is associated with organ vascular malformations in hereditary hemorrhagic telangiectasia patients with ENG mutations, but not in patients with ACVRL1 mutations.","date":"2015","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/25847705","citation_count":15,"is_preprint":false},{"pmid":"30244195","id":"PMC_30244195","title":"Genome sequencing reveals a deep intronic splicing ACVRL1 mutation hotspot in Hereditary Haemorrhagic Telangiectasia.","date":"2018","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30244195","citation_count":14,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53887,"output_tokens":8864,"usd":0.147311},"stage2":{"model":"claude-opus-4-6","input_tokens":12783,"output_tokens":5606,"usd":0.306098},"total_usd":0.453409,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2003,\n      \"finding\": \"ALK1 induces Smad1/5 phosphorylation in endothelial cells, leading to increased proliferation and migration, while acting as an antagonist of the ALK5/Smad2/3 pathway. ALK5 kinase activity is required for TGFβ-dependent recruitment of ALK1 into a TGFβ receptor complex and for optimal ALK1 activation. ALK1 directly antagonizes ALK5/Smad signaling.\",\n      \"method\": \"Endothelial cell signaling assays, loss-of-function (ALK5-deficient cells), reporter assays, co-immunoprecipitation\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (KO cells, reporter assays, Co-IP), replicated context, high citation count\",\n      \"pmids\": [\"14580334\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"ALK1 specifically phosphorylates and activates Smad1. The specificity of Smad1 recognition by ALK1 requires both the receptor L45 loop and two surface structures on the Smad1 MH2 domain (L3 loop and alpha-helix 1), a mechanism distinct from that used by BMPR-I to activate Smad1.\",\n      \"method\": \"In vitro kinase assays, mutagenesis of L45 loop and Smad MH2 domain, specificity mapping\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with mutagenesis, foundational mechanistic study\",\n      \"pmids\": [\"9920917\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"TGFβ1 and TGFβ3, as well as an unidentified serum ligand, can activate ALK1 signaling. The ALK1/TGFβ interaction is mediated by the TGFβ type II receptor. Endoglin binds both ALK1 and TGFβ type I receptor. HHT-associated missense mutations in the ALK1 extracellular domain abrogate signaling.\",\n      \"method\": \"Chimeric receptor signaling assay (kinase domain swap), PAI-1 promoter reporter, co-immunoprecipitation, mutagenesis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — chimeric receptor functional assay with mutagenesis and co-IP\",\n      \"pmids\": [\"10187774\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Endoglin is required for efficient TGFβ/ALK1 signaling; endothelial cells lacking endoglin show reduced ALK1 signaling and increased ALK5 signaling. Endoglin promotes endothelial cell proliferation by favoring the ALK1 pathway, which indirectly inhibits ALK5 signaling.\",\n      \"method\": \"Endoglin-deficient endothelial cells, reporter assays, cell proliferation assays, Smad phosphorylation\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO cells with multiple readouts (signaling, proliferation), high citation count\",\n      \"pmids\": [\"15385967\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Disruption of acvrl1 (alk1) in zebrafish results in increased endothelial cell number in specific cranial vessels, causing dilated arteriovenous malformations, establishing ALK1 as a TGFβ type I receptor essential for restricting endothelial cell number during vascular development.\",\n      \"method\": \"Zebrafish genetic mutant (violet beauregarde), in situ hybridization, endothelial cell counting\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic loss-of-function with specific cellular phenotype, high citation count\",\n      \"pmids\": [\"12050147\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Of 29 TGFβ-related ligands screened, only BMP9 and BMP10 display high-affinity binding to the ALK1 extracellular domain (ALK1-Fc). ALK1-Fc inhibits BMP9-mediated Id-1 expression in endothelial cells and inhibits cord formation on Matrigel.\",\n      \"method\": \"Surface plasmon resonance ligand screen, cell-based Id-1 reporter assay, Matrigel cord formation assay\",\n      \"journal\": \"Molecular cancer therapeutics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — SPR binding assay plus functional cell assays, identifies high-affinity ligands\",\n      \"pmids\": [\"20124460\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Conditional endothelial deletion of Alk1 in mice produces severe vascular malformations mimicking all pathological features of HHT2, whereas conditional deletion of Alk5 or Tgfbr2 in endothelial cells (or Alk5 inhibition in zebrafish) does not affect vessel morphogenesis, demonstrating that ALK1's role in HHT pathogenesis is independent of ALK5 and TGFBR2 in vivo.\",\n      \"method\": \"Conditional endothelial-specific knockout mice (Alk1, Alk5, Tgfbr2), zebrafish Alk5 inhibition, vascular phenotype analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple conditional KO lines with direct phenotypic comparison, genetic epistasis\",\n      \"pmids\": [\"17911384\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"ALK1 inhibits angiogenesis by synergizing with the Notch pathway in stalk cells. ALK1-dependent SMAD signaling synergizes with activated Notch to induce HEY1 and HEY2 expression, thereby repressing VEGF signaling, tip cell formation, and endothelial sprouting. BMP9 (high-affinity ALK1 ligand) rescues hypersprouting caused by Notch inhibition.\",\n      \"method\": \"Postnatal mouse retinal vascular assays, Notch/Alk1 combined blockade, BMP9 rescue, reporter assays in cultured endothelial cells\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic/pharmacological manipulations with defined molecular (HEY1/2) and cellular readouts\",\n      \"pmids\": [\"22421041\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Cardiac-derived BMP10 is the crucial circulating ligand for endothelial ALK1 in embryonic vascular development. Blood flow promotes ALK1 activity by inducing alk1 expression and distributing BMP10, and together these limit endothelial cell number and stabilize nascent arterial caliber.\",\n      \"method\": \"Zebrafish bmp10 loss-of-function, alk1 expression rescue experiments, flow manipulation, endothelial cell quantification\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in zebrafish, multiple loss-of-function alleles, defined cellular and molecular phenotypes\",\n      \"pmids\": [\"23863480\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The crystal structure of the ALK1 intracellular kinase domain was determined. ALK1 mediates signaling via phosphorylation of SMAD1/5/8. A small molecule kinase inhibitor (K02288) inhibits BMP9-induced SMAD1/5/8 phosphorylation in endothelial cells and reduces both SMAD-dependent and Notch-dependent transcriptional responses.\",\n      \"method\": \"Crystal structure determination of ALK1 kinase domain, in vitro kinase inhibition assay, SMAD phosphorylation, reporter assays, endothelial sprouting assays\",\n      \"journal\": \"Angiogenesis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure plus functional inhibitor assays with multiple readouts\",\n      \"pmids\": [\"25557927\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Crystal structures of the BMP10:ALK1 complex (2.3 Å) and prodomain-bound BMP9:ALK1 complex (3.3 Å) revealed a tripartite recognition mechanism defining BMP9 and BMP10 specificity for ALK1. Introduction of BMP10-specific residues into BMP9 reduced signaling activity, validating the tripartite mechanism.\",\n      \"method\": \"X-ray crystallography, mutagenesis, C2C12 cell signaling assays, SPR\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structures with mutagenesis validation and functional assays\",\n      \"pmids\": [\"32238803\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"NMR structure of the ALK1 extracellular domain determined; SPR identified residues in the β4-β5 loop critical for BMP9 binding. The altered conformation of the β4-β5 loop (compared to ALK3) necessitates a ~40° rotated binding mode for BMP9, with a large hydrophobic interface.\",\n      \"method\": \"NMR structure determination, SPR binding assays, mutagenesis\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — NMR structure with SPR mutational validation\",\n      \"pmids\": [\"22799562\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Smad7 and protein phosphatase 1α (PP1α) are critical determinants of the duration of TGFβ/ALK1 signaling. TGFβ/ALK1 upregulates Smad7 and PP1α; PP1α interacts with ALK1 and this association is potentiated by Smad7; PP1α dephosphorylates ALK1 to terminate Smad1/5 phosphorylation.\",\n      \"method\": \"siRNA knockdown, ectopic expression, co-immunoprecipitation, phosphatase inhibition assay, reporter assays\",\n      \"journal\": \"BMC cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP, siRNA and overexpression with consistent outcomes, enzymatic assay\",\n      \"pmids\": [\"16571110\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ALK1 mediates LDL uptake and transcytosis in endothelial cells via an unusual non-degradative endocytic pathway. ALK1 binds LDL with lower affinity than LDLR and saturates only at hypercholesterolemic concentrations. Endothelium-specific ablation of Alk1 in Ldlr-KO mice reduces LDL uptake into aortic endothelium.\",\n      \"method\": \"Genome-wide RNAi screen, LDL binding/uptake assays, transcytosis assays, endothelial-specific Alk1 KO mice\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — genome-wide screen plus in vitro and in vivo validation with genetic KO\",\n      \"pmids\": [\"27869117\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Genetic deletion of ALK1 in arterial endothelial cells substantially limits LDL accumulation, macrophage infiltration, and atherosclerosis without affecting cholesterol levels. A selective monoclonal antibody blocking ALK1 LDL transcytosis (but not BMP9 signaling) dramatically reduces plaque formation in Ldlr-KO mice.\",\n      \"method\": \"Endothelial-specific Alk1 KO mice, monoclonal antibody blockade, atherosclerosis plaque quantification, LDL transcytosis assay\",\n      \"journal\": \"Nature cardiovascular research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic KO plus antibody intervention with specific molecular dissection of LDL vs. BMP9 pathways\",\n      \"pmids\": [\"39196046\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"LUBAC conjugates linear ubiquitin chains onto ALK1, inhibiting its enzyme activity and Smad1/5 activation. OTULIN deubiquitinates ALK1 to promote Smad1/5 activation. EC-specific Otulin deletion causes arteriovenous malformations. HHT2 patient-derived mutant ALK1 exhibits excessive linear ubiquitination and increased HOIP binding.\",\n      \"method\": \"EC-specific Otulin KO mice, co-immunoprecipitation, ubiquitination assays, SMAD signaling assays, constitutively active ALK1 knockin rescue\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic models, Co-IP, ubiquitination assays, rescue experiment with defined molecular mechanism\",\n      \"pmids\": [\"34157307\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"ALK1 localizes to endothelial caveolae and physically interacts with caveolin-1 via the caveolin-1 scaffolding domain and the ALK1 caveolin-1 binding motif. Caveolin-1 enhances TGFβ/ALK1 signaling (opposite to its effect on ALK5). Caveolin-1 suppression abrogates ALK1 signaling.\",\n      \"method\": \"Confocal microscopy, cholesterol depletion, co-immunoprecipitation, domain mapping, ALK1-specific luciferase reporters, siRNA knockdown\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP with domain mapping, localization plus functional consequence demonstrated\",\n      \"pmids\": [\"18065769\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Nuclear receptor LXRβ binds specifically to the cytoplasmic domain of ALK1 in vitro and in vivo. Activated ALK1 causes translocation of LXRβ from nucleus to cytoplasm, and ALK1 phosphorylates LXRβ primarily on serine residues. LXRβ subsequently inhibits ALK1- and ALK2-mediated transcriptional responses.\",\n      \"method\": \"In vitro binding assay, co-immunoprecipitation, subcellular fractionation, phosphorylation assay, transcriptional reporter assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP and functional assays from a single lab, moderate follow-up in the field\",\n      \"pmids\": [\"12393874\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"SnoN binds directly to ALK1 on the plasma membrane upon ligand binding and facilitates the interaction between ALK1 and Smad1/5, enhancing Smad1/5 phosphorylation. Disruption of SnoN-Smad1/5 interaction impairs Smad1/5 activation, upregulates Smad2/3 activity, and causes arteriovenous malformations and embryonic lethality.\",\n      \"method\": \"Co-immunoprecipitation, plasma membrane binding assay, Smad phosphorylation assays, genetic mouse model with embryonic phenotype\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct protein interaction mapping, loss-of-function with clear in vivo phenotype and defined molecular mechanism\",\n      \"pmids\": [\"24019535\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ALK1 controls arterial endothelial cell migration within lumenized vessels (rather than proliferation). In alk1-deficient zebrafish, migration against blood flow direction is dampened and migration in the direction of flow is enhanced, altering endothelial cell distribution and arterial caliber.\",\n      \"method\": \"Live imaging of zebrafish endothelial cells, cell tracking in alk1 mutants, proliferation assays\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct live imaging of cell behavior in genetic mutant with specific cellular phenotype\",\n      \"pmids\": [\"27287800\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Endothelial-specific depletion of Acvrl1 leads to venous enlargement, vascular hyperbranching, and arteriovenous malformations in neonatal retinal angiogenesis. Loss of Acvrl1 is associated with reduced arterial Jag1 expression, decreased pSmad1/5/8, and increased endothelial cell proliferation. Endoglin is markedly downregulated in Acvrl1-depleted endothelial cells, placing Endoglin downstream of Acvrl1 signaling.\",\n      \"method\": \"Endothelial-specific Acvrl1 conditional KO mice (neonatal and adult), retinal imaging, immunostaining, pSmad quantification\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean endothelial-specific KO with multiple molecular and morphological readouts\",\n      \"pmids\": [\"24896812\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"BMP9/ALK1 signaling represses VEGF-mediated PI3K activity by promoting PTEN activity. Loss of ALK1 function results in increased PI3K pathway activity and vascular hyperplasia. Pharmacological PI3K inhibition rescues vascular hyperplasia of ALK1+/- retinas.\",\n      \"method\": \"ALK1+/- heterozygous mice, retinal endothelial cell analysis, PI3K/PTEN signaling assays, pharmacological PI3K inhibition rescue, HHT2 patient biopsy analysis\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic model plus pharmacological rescue with defined molecular mechanism, validated in human biopsies\",\n      \"pmids\": [\"29449337\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"BMP-9 binding to ALK-1 triggers extensive endocytosis of ALK1 mediated by caveolin-1 (CAV-1) and dynamin-2 but not clathrin. CAV-1 knockdown reduces BMP-9-mediated ALK1 internalization, BMP-9-dependent signaling, and gene expression. LDL reduces BMP-9-induced SMAD1/5 phosphorylation, and BMP-9-mediated ALK1 internalization strongly reduces LDL transcytosis.\",\n      \"method\": \"Endocytosis assays, siRNA knockdown (CAV-1, DNM2, clathrin), SMAD1/5 phosphorylation, LDL transcytosis assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple siRNA knockdowns with consistent mechanistic outcome across signaling and transcytosis readouts\",\n      \"pmids\": [\"33097593\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Functional analysis of 19 ALK1 mutants reproducing HHT2 mutations showed that most are expressed and reach the cell surface but are defective in BMP9 signaling, while extracellular mutants lose BMP9 binding. None exhibit dominant-negative effects on wild-type ALK1 activity, supporting a haploinsufficiency model for HHT2.\",\n      \"method\": \"Site-directed mutagenesis, BMP9 signaling reporter assays, cell surface expression assays, BMP9 binding assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — systematic mutagenesis of 19 HHT2 alleles with functional assays, mechanistic conclusion about haploinsufficiency\",\n      \"pmids\": [\"20501893\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"BMP9/BMP10/ALK1 signaling controls the identity and self-renewal of Kupffer cells (KCs) through a Smad4-dependent pathway. ALK1 is dispensable for macrophages in lung, kidney, spleen, and brain. ALK1 deletion causes KC loss over time, replaced by monocyte-derived macrophages with reduced VSIG4 expression, impairing Listeria monocytogenes capture.\",\n      \"method\": \"Macrophage/KC-specific Alk1 KO mice, flow cytometry, bacterial infection challenge, immunostaining\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic KO with defined cellular and functional phenotype across multiple tissue macrophage types\",\n      \"pmids\": [\"34874921\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"FOXF1 transcription factor, acting synergistically with ETS factor FLI1, activates the ACVRL1 promoter. Loss of FOXF1 reduces BMP9/ACVRL1 signaling in pulmonary endothelial progenitor cells. Nanoparticle-mediated silencing of ACVRL1 in newborn mice decreases neonatal lung angiogenesis. BMP9 treatment restores lung angiogenesis in ACVRL1-deficient mice.\",\n      \"method\": \"scRNA-seq, ACVRL1 promoter reporter assays, FOXF1/FLI1 co-transfection, nanoparticle siRNA delivery KO in vivo, BMP9 rescue\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — promoter assay identifies upstream regulators, in vivo KO and rescue with defined angiogenic phenotype\",\n      \"pmids\": [\"35440116\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"AMPK activation by metformin inhibits ALK1-mediated Smad1/5 phosphorylation and BMP9-induced tube formation. This is mediated by AMPK-induced upregulation of Smurf1, leading to degradation of ALK1 protein.\",\n      \"method\": \"Pharmacological AMPK activation, dominant-negative and constitutively-active AMPKα1 constructs, Smad1/5 phosphorylation assays, Smurf1 expression assays, Matrigel angiogenesis assay\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic and pharmacological tools, single lab, moderate mechanistic follow-up\",\n      \"pmids\": [\"28427181\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Alk1 expression in arterial endothelial cells requires blood flow. In alk1-deficient zebrafish, initial increases in endothelial cell number are independent of blood flow, but later increases and AVM development are flow-dependent. Alk1 transduces hemodynamic forces into a biochemical signal limiting nascent arterial caliber.\",\n      \"method\": \"Zebrafish alk1 mutant analysis, blood flow manipulation, flow-responsive gene expression analysis, endothelial cell counting\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic mutant with blood flow manipulation, clear temporal dissection of flow-dependent vs. independent effects\",\n      \"pmids\": [\"21389051\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"In COS-1 cells, ALK1 is found in TGFβ1 and TGFβ3 receptor complexes in association with endoglin and TβRII. In HUVEC, ALK1 and endoglin interact directly by co-immunoprecipitation in the absence of ligand, forming a transient association.\",\n      \"method\": \"Co-immunoprecipitation, immunoprecipitation/western blot in HUVEC and COS-1 cells, novel anti-ALK1 polyclonal antibody\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single Co-IP from two cell systems, but consistent findings across multiple patient-derived HUVEC\",\n      \"pmids\": [\"10767348\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"In chondrocytes, BMP9 potently induces pSmad1/5 phosphorylation and a hypertrophy-like state (bAlpl, bColX expression). BMP9-induced Smad1/5 activation and hypertrophy markers are antagonized by TGFβ1.\",\n      \"method\": \"Primary bovine chondrocyte cultures, BMP9 stimulation, Western blot (pSmad), qPCR, reporter assay\",\n      \"journal\": \"Osteoarthritis and cartilage\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro with multiple readouts from single lab\",\n      \"pmids\": [\"25681563\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Somatic mutations resulting in bi-allelic loss of ACVRL1 (in trans with germline mutation) were identified in 9/19 HHT telangiectasia by next-generation sequencing, supporting a Knudsonian two-hit mechanism for focal vascular malformation development rather than haploinsufficiency alone.\",\n      \"method\": \"Next-generation sequencing of telangiectasia tissue, phase determination of somatic/germline mutations\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — sequencing-based finding establishing mechanism; single study with 19 lesions\",\n      \"pmids\": [\"31630786\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Glucocorticoids promote TGFβ signaling through the Acvrl1/Smad1/5/8 axis and blunt Tgfbr1/Smad2/3 signaling in lung fibroblasts. This shift is mediated by glucocorticoid-induced upregulation of the accessory receptor Tgfbr3 (betaglycan), which acts as a 'switch' potentiating Acvrl1/Smad1 while blunting Tgfbr1/Smad2/3 signaling.\",\n      \"method\": \"Multiple glucocorticoid treatments, primary lung fibroblasts and endothelial cells, Smad phosphorylation, siRNA for Tgfbr3, in vivo dexamethasone administration to mice\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple cell types and in vivo validation, single lab\",\n      \"pmids\": [\"24347165\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Hepatic endothelial ALK1 signaling (via BMP9/ALK1/ID axis) regulates Wnt2 and R-spondin-3 expression in liver sinusoidal endothelial cells, maintaining metabolic liver zonation. Loss of ALK1 in hepatic endothelial cells leads to vascular malformations, loss of LSEC identity, and disruption of metabolic liver zonation.\",\n      \"method\": \"LSEC-selective Acvrl1 KO mice (Stab2-iCreF3), transcriptomics, ID1-3 function inhibition, in vitro ALK1 stimulation/inhibition in LSEC\",\n      \"journal\": \"Hepatology (Baltimore, Md.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell-type-specific KO with transcriptomic and functional validation, human HHT liver specimen confirmation\",\n      \"pmids\": [\"35776660\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"BMP9 induces EphrinB2 expression in arterial endothelial cells through an ALK1-BMPRII/ActRII-ID1/ID3-dependent pathway. Loss of ALK1 reduces EphrinB2 expression, increases VEGFR2 expression, and enhances capillary sprouting and arteriovenous anastomosis.\",\n      \"method\": \"siRNA knockdown (ALK1, BMPRII, ActRII, ID1, ID3), BMP9 stimulation, immunostaining, in vitro angiogenesis assay\",\n      \"journal\": \"Angiogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — systematic knockdown of pathway components with defined molecular and cellular readouts, single lab\",\n      \"pmids\": [\"22622516\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In zebrafish, combined loss of bmp10 and bmp10-like (but not bmp9) results in embryonic lethal cranial AVMs indistinguishable from acvrl1 mutants. In juvenile-to-adult period, bmp10 (not bmp9 or bmp10-like) is the non-redundant ALK1 ligand required to maintain the post-embryonic vasculature.\",\n      \"method\": \"Zebrafish genetic mutants (bmp9, bmp10, bmp10-like single and compound), vascular phenotype analysis\",\n      \"journal\": \"Angiogenesis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic mutant combinations establishing ligand hierarchy, clean phenotypic readout\",\n      \"pmids\": [\"31828546\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ALK1 is localized to Caveolin-1-positive early endosomes under atheroprone (low laminar) shear stress conditions, and this endosomal compartment constitutes a signaling hub for BMP9-ALK1-Endoglin-SMAD1 signaling. Endoglin knockdown under these conditions exacerbates SMAD1/5 phosphorylation.\",\n      \"method\": \"Confocal microscopy, subcellular fractionation, siRNA knockdown, long-term shear stress application in HUVECs\",\n      \"journal\": \"BMC biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization with functional consequence, single lab\",\n      \"pmids\": [\"36171573\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Functional analysis of 11 HHT2-related ALK1 kinase domain mutations revealed two mechanisms: some mutations generate a dominant-negative effect while others result in null phenotypes via loss of protein expression or receptor activity.\",\n      \"method\": \"Site-directed mutagenesis, reporter assay in mammalian cells, zebrafish embryo injection\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — systematic mutagenesis with in vitro and in vivo functional validation, single lab\",\n      \"pmids\": [\"16282348\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ACVRL1 (ALK1) is an endothelial-specific transmembrane serine/threonine kinase receptor for BMP9 and BMP10 (high-affinity ligands) that signals by phosphorylating Smad1/5 (facilitated by SnoN, regulated by Smad7/PP1α-mediated dephosphorylation and LUBAC/OTULIN-mediated linear ubiquitination), antagonizes ALK5/Smad2/3 signaling to promote endothelial cell proliferation and directed migration, cooperates with Notch to repress tip cell formation, represses PI3K activity via PTEN to maintain vascular quiescence, mediates non-degradative LDL transcytosis in endothelial cells via caveolin-1-dependent endocytosis, and its loss causes arteriovenous malformations through a two-hit (haploinsufficiency plus somatic second-hit) mechanism involving flow-dependent failure to limit arterial caliber.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ACVRL1 (ALK1) is an endothelial type I serine/threonine kinase receptor that transduces BMP9/BMP10 signals through Smad1/5 phosphorylation to control vascular morphogenesis, endothelial quiescence, and arterial caliber. ALK1 recognizes BMP9 and BMP10 as high-affinity ligands via a tripartite binding mechanism involving its β4-β5 loop, signals through caveolin-1-dependent endocytosis, and synergizes with Notch to repress tip cell formation and VEGF signaling; its activity is positively regulated by the adaptor SnoN and endoglin, and negatively regulated by Smad7/PP1α-mediated dephosphorylation and LUBAC-mediated linear ubiquitination [PMID:20124460, PMID:32238803, PMID:22421041, PMID:24019535, PMID:15385967, PMID:16571110, PMID:34157307, PMID:33097593]. Beyond canonical BMP signaling, ALK1 mediates non-degradative LDL transcytosis across endothelium; arterial endothelial-specific ALK1 deletion reduces atherosclerotic plaque formation, and a monoclonal antibody selectively blocking LDL transcytosis without disrupting BMP9 signaling recapitulates this protection [PMID:27869117, PMID:39196046]. Loss-of-function mutations in ACVRL1 cause hereditary hemorrhagic telangiectasia type 2 (HHT2), with somatic second-hit mutations driving focal arteriovenous malformations through a Knudsonian two-hit mechanism compounded by flow-dependent failure to limit arterial caliber [PMID:20501893, PMID:31630786, PMID:21389051].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Establishing ALK1 as a Smad1-specific kinase resolved which downstream effector this orphan receptor activated, revealing that specificity depends on the L45 loop and Smad1 MH2 domain surfaces distinct from canonical BMP receptors.\",\n      \"evidence\": \"In vitro kinase assays with L45 loop and MH2 domain mutagenesis\",\n      \"pmids\": [\"9920917\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous ligands for ALK1 not yet identified\", \"In vivo relevance of Smad1 specificity not demonstrated\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Demonstrating that TGFβ activates ALK1 via the type II receptor TβRII and that endoglin participates in the complex identified ALK1 as a TGFβ superfamily receptor and explained why HHT mutations in both ALK1 and endoglin cause overlapping disease.\",\n      \"evidence\": \"Chimeric receptor signaling assays, co-immunoprecipitation, HHT missense mutation analysis\",\n      \"pmids\": [\"10187774\", \"10767348\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TGFβ is the physiologically relevant ligand in vivo remained uncertain\", \"Endoglin's precise role in promoting ALK1 vs. ALK5 signaling not yet defined\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Genetic loss of alk1 in zebrafish produced dilated AVMs with excess endothelial cells, establishing for the first time that ALK1 restricts endothelial cell number and prevents arteriovenous shunting in vivo.\",\n      \"evidence\": \"Zebrafish alk1 mutant (violet beauregarde), endothelial cell counting, in situ hybridization\",\n      \"pmids\": [\"12050147\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which ALK1 limits endothelial cell number unknown\", \"Mammalian in vivo confirmation pending\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Showing that ALK1 directly antagonizes ALK5/Smad2/3 signaling and requires ALK5 kinase activity for its own activation established the ALK1-ALK5 balance model governing endothelial proliferation versus quiescence.\",\n      \"evidence\": \"ALK5-deficient endothelial cells, reporter assays, co-immunoprecipitation\",\n      \"pmids\": [\"14580334\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the ALK5-dependence of ALK1 activation applies in all vascular beds not tested\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Demonstrating that endoglin-null endothelial cells show impaired ALK1 signaling and enhanced ALK5 signaling resolved endoglin's function as a facilitator that biases TGFβ signaling toward the ALK1/Smad1/5 arm.\",\n      \"evidence\": \"Endoglin-deficient endothelial cells, Smad phosphorylation and proliferation assays\",\n      \"pmids\": [\"15385967\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for endoglin-ALK1 cooperation unknown\", \"Whether endoglin is required for BMP9/10-ALK1 signaling not addressed\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identification of Smad7 and PP1α as negative regulators that dephosphorylate ALK1 defined the signal termination mechanism for the ALK1/Smad1/5 pathway.\",\n      \"evidence\": \"Co-immunoprecipitation, siRNA, phosphatase inhibition assays, reporter assays\",\n      \"pmids\": [\"16571110\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of PP1α-mediated ALK1 dephosphorylation not tested\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Conditional endothelial Alk1 deletion in mice recapitulated HHT2 while Alk5 and Tgfbr2 deletion did not, overturning the model that ALK1 requires ALK5/TβRII in vivo and implying a distinct ligand drives ALK1 in endothelium.\",\n      \"evidence\": \"Conditional endothelial-specific KO mice (Alk1, Alk5, Tgfbr2), zebrafish ALK5 inhibition\",\n      \"pmids\": [\"17911384\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The identity of the in vivo ALK1 ligand in endothelium remained unknown\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Localization of ALK1 to caveolae and identification of a direct caveolin-1 interaction that enhances ALK1 signaling established the membrane microdomain required for ALK1 signal transduction.\",\n      \"evidence\": \"Confocal microscopy, co-immunoprecipitation with domain mapping, siRNA knockdown of caveolin-1\",\n      \"pmids\": [\"18065769\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether caveolin-1 dependence extends to BMP9/10-specific ALK1 signaling not yet tested\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"A systematic screen of 29 TGFβ-family ligands identified BMP9 and BMP10 as the sole high-affinity ALK1 ligands, resolving a long-standing question about the physiological activators of ALK1 in endothelium.\",\n      \"evidence\": \"Surface plasmon resonance ligand screen, Id-1 reporter and Matrigel assays\",\n      \"pmids\": [\"20124460\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contributions of BMP9 vs. BMP10 in vivo unclear\", \"Whether other ligands activate ALK1 in non-endothelial contexts not excluded\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Systematic functional analysis of 19 HHT2 mutations showed most retain surface expression but lose BMP9 signaling without dominant-negative effects, supporting haploinsufficiency as the primary disease mechanism.\",\n      \"evidence\": \"Site-directed mutagenesis, BMP9 reporter and binding assays, surface expression quantification\",\n      \"pmids\": [\"20501893\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Somatic second-hit mechanism not yet investigated\", \"Earlier study found some kinase domain mutations with dominant-negative activity (PMID:16282348), creating unresolved discrepancy\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Demonstrating that blood flow induces alk1 expression and that AVM progression is flow-dependent established ALK1 as a mechanosensitive transducer that converts hemodynamic force into a biochemical signal limiting arterial caliber.\",\n      \"evidence\": \"Zebrafish alk1 mutant with blood flow manipulation, endothelial cell counting\",\n      \"pmids\": [\"21389051\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism of flow-induced ALK1 expression unknown\", \"Whether this applies to mammalian vasculature not directly shown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Showing that ALK1/Smad signaling synergizes with Notch to induce HEY1/HEY2 and repress tip cell formation unified two major pathways controlling angiogenic sprouting and explained why ALK1 loss causes hypersprouting.\",\n      \"evidence\": \"Postnatal mouse retinal assays, combined Notch/Alk1 blockade, BMP9 rescue\",\n      \"pmids\": [\"22421041\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct physical interaction between ALK1-Smad and Notch pathways at chromatin level not demonstrated\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"NMR and crystal structures of the ALK1 extracellular domain and kinase domain provided the first atomic-level understanding of ALK1 architecture and revealed an unusual β4-β5 loop conformation requiring a rotated BMP9 binding mode.\",\n      \"evidence\": \"NMR and X-ray crystallography, SPR mutagenesis validation\",\n      \"pmids\": [\"22799562\", \"25557927\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full ternary complex structure with type II receptor not available\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identification of cardiac BMP10 as the crucial circulating ALK1 ligand during embryonic vascular development, distributed by blood flow, connected ligand identity, hemodynamics, and ALK1 signaling into an integrated model of arterial caliber control.\",\n      \"evidence\": \"Zebrafish bmp10 loss-of-function, flow manipulation, alk1 expression rescue\",\n      \"pmids\": [\"23863480\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether BMP9 serves a distinct postnatal role not resolved in this model\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Discovery that SnoN directly binds ALK1 at the plasma membrane and facilitates Smad1/5 phosphorylation identified a previously unknown positive regulator whose disruption causes AVMs and embryonic lethality.\",\n      \"evidence\": \"Co-immunoprecipitation, Smad phosphorylation assays, genetic mouse model\",\n      \"pmids\": [\"24019535\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether SnoN facilitates BMP9 vs. BMP10 signaling differentially is untested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"A genome-wide RNAi screen identified ALK1 as a mediator of non-degradative LDL transcytosis in endothelial cells, revealing a signaling-independent function of ALK1 with direct relevance to cholesterol transport.\",\n      \"evidence\": \"Genome-wide RNAi screen, LDL binding/uptake/transcytosis assays, endothelial-specific Alk1 KO in Ldlr-KO mice\",\n      \"pmids\": [\"27869117\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for ALK1-LDL interaction unknown\", \"Whether LDL transcytosis and BMP signaling can be pharmacologically separated not yet shown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Live imaging in alk1 mutant zebrafish revealed that ALK1 controls directed endothelial migration against blood flow rather than proliferation in lumenized arteries, refining the cellular mechanism of AVM formation.\",\n      \"evidence\": \"Live endothelial cell tracking in zebrafish alk1 mutants, proliferation quantification\",\n      \"pmids\": [\"27287800\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mediators downstream of ALK1 that direct migration not identified\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrating that ALK1 loss increases PI3K activity through reduced PTEN function, and that PI3K inhibition rescues ALK1-haploinsufficient vascular hyperplasia, identified a druggable effector pathway downstream of ALK1.\",\n      \"evidence\": \"ALK1+/- mice, retinal analysis, PI3K/PTEN signaling assays, pharmacological rescue, HHT2 patient biopsies\",\n      \"pmids\": [\"29449337\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which Smad1/5 signaling activates PTEN not defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identification of somatic second-hit ACVRL1 mutations in HHT telangiectasia supported a Knudsonian two-hit model, explaining why vascular malformations are focal despite germline haploinsufficiency.\",\n      \"evidence\": \"Next-generation sequencing of 19 telangiectasia lesions, phasing of somatic and germline mutations\",\n      \"pmids\": [\"31630786\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Only 9/19 lesions showed biallelic loss; alternative mechanisms in remaining lesions unknown\", \"Independent replication in larger cohorts needed\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Crystal structures of BMP10:ALK1 and prodomain-bound BMP9:ALK1 complexes defined the tripartite recognition mechanism for ligand specificity, explaining why only BMP9 and BMP10 activate ALK1.\",\n      \"evidence\": \"X-ray crystallography (2.3 and 3.3 Å), mutagenesis, SPR, cell signaling assays\",\n      \"pmids\": [\"32238803\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full hexameric complex with type II receptor and endoglin not structurally resolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showing that BMP9-triggered ALK1 internalization is caveolin-1/dynamin-2-dependent and competes with LDL transcytosis mechanistically linked ALK1's signaling and transport functions through shared endocytic machinery.\",\n      \"evidence\": \"Endocytosis assays with siRNA knockdown of CAV-1, DNM2, and clathrin; SMAD1/5 phosphorylation and LDL transcytosis quantification\",\n      \"pmids\": [\"33097593\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether caveolar vs. endosomal ALK1 pools are functionally distinct in vivo is unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Discovery that LUBAC conjugates linear ubiquitin chains onto ALK1 to inhibit its kinase activity, reversed by OTULIN, identified a novel post-translational regulatory layer; HHT2-mutant ALK1 shows excessive linear ubiquitination, linking this mechanism directly to disease.\",\n      \"evidence\": \"EC-specific Otulin KO mice, ubiquitination assays, co-immunoprecipitation, constitutively active ALK1 rescue\",\n      \"pmids\": [\"34157307\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which specific lysine residues on ALK1 are ubiquitinated not mapped\", \"Whether LUBAC/OTULIN regulation affects LDL transcytosis is unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Extending ALK1 function beyond endothelium, BMP9/BMP10/ALK1 signaling was shown to control Kupffer cell identity and self-renewal through Smad4, with ALK1 loss causing KC replacement by monocyte-derived macrophages and impaired pathogen capture.\",\n      \"evidence\": \"Macrophage/KC-specific Alk1 KO mice, flow cytometry, Listeria infection challenge\",\n      \"pmids\": [\"34874921\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream transcriptional targets of ALK1 in Kupffer cells not fully characterized\", \"Whether this represents a direct cell-autonomous function or paracrine effect not fully excluded\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identification of FOXF1 and FLI1 as transcriptional activators of the ACVRL1 promoter, combined with in vivo demonstration that ACVRL1 silencing impairs neonatal lung angiogenesis, defined the upstream regulatory circuit controlling ALK1 expression in pulmonary endothelium.\",\n      \"evidence\": \"scRNA-seq, promoter reporter assays, nanoparticle siRNA in vivo knockdown, BMP9 rescue\",\n      \"pmids\": [\"35440116\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether FOXF1-dependent regulation is specific to lung endothelium or generalizable is unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Hepatic endothelial ALK1 signaling through the BMP9/ALK1/ID axis was shown to regulate Wnt2 and R-spondin-3 expression, maintaining liver sinusoidal endothelial cell identity and metabolic zonation.\",\n      \"evidence\": \"LSEC-selective Acvrl1 KO mice, transcriptomics, ID function inhibition, HHT liver specimens\",\n      \"pmids\": [\"35776660\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ALK1 regulates Wnt signaling in other organ vasculatures is unexplored\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"A monoclonal antibody that selectively blocks ALK1-mediated LDL transcytosis without disrupting BMP9 signaling dramatically reduced atherosclerosis, demonstrating therapeutic separability of ALK1's dual functions.\",\n      \"evidence\": \"Endothelial-specific Alk1 KO mice, selective monoclonal antibody, plaque quantification in Ldlr-KO mice\",\n      \"pmids\": [\"39196046\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Long-term vascular safety of selective LDL-transcytosis blockade not assessed\", \"Structural epitope on ALK1 responsible for LDL binding versus BMP9 binding not mapped\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis for ALK1-LDL interaction, how flow-sensing is molecularly transduced through ALK1, the full hexameric receptor complex structure with type II receptors, and whether the two-hit mechanism accounts for all HHT2 vascular malformations.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structural model of ALK1-LDL binding interface\", \"Mechanotransduction mechanism linking shear stress to ALK1 activation undefined\", \"Complete receptor signaling complex structure not solved\", \"Two-hit model only validated in ~50% of lesions\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 9, 12, 15, 18]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 7, 21]},\n      {\"term_id\": \"GO:0038024\", \"supporting_discovery_ids\": [13, 14, 22]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [16, 18, 22, 35]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [22, 35]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [22, 35]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 5, 7, 9, 10, 12, 15, 18, 21]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [4, 8, 20, 27]},\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [13, 14, 22]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [23, 30, 36]}\n    ],\n    \"complexes\": [\n      \"TGFβ/BMP receptor complex (ALK1-TβRII-endoglin)\",\n      \"BMP9/10-ALK1-BMPRII/ActRII signaling complex\"\n    ],\n    \"partners\": [\n      \"ENG\",\n      \"SMAD1\",\n      \"SMAD5\",\n      \"CAV1\",\n      \"SKIL\",\n      \"SMAD7\",\n      \"PPP1CA\",\n      \"HOIP\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}